

REVIEW ARTICLE OPEN



Circular RNAs in neurological conditions – computational identification, functional validation, and potential clinical applications

Oak Hatzimanolis¹, Alex M. Sykes¹ and Alexandre S. Cristino¹

© Crown 2025

Non-coding RNAs (ncRNAs) have gained significant attention in recent years due to advancements in biotechnology, particularly high-throughput total RNA sequencing. These developments have led to new understandings of non-coding biology, revealing that approximately 80% of non-coding regions in the genome possesses biochemical functionality. Among ncRNAs, circular RNAs (circRNAs), first identified in 1976, have emerged as a prominent research field. CircRNAs are abundant in most human cell types, evolutionary conserved, highly stable, and formed by back-splicing events which generate covalently closed ends. Notably, circRNAs exhibit high expression levels in neural tissue and perform diverse biochemical functions, including acting as molecular sponges for microRNAs, interacting with RNA-binding proteins to regulate their availability and activity, modulating transcription and splicing, and even translating into functional peptides in some cases. Recent advancements in computational and experimental methods have enhanced our ability to identify and validate circRNAs, providing valuable insights into their biological roles. This review focuses on recent developments in circRNA research as they related to neuropsychiatric and neurodegenerative conditions. We also explore their potential applications in clinical diagnostics, therapeutics, and future research directions. CircRNAs remain a relatively underexplored area of non-coding biology, particularly in the context of neurological disorders. However, emerging evidence supports their role as critical players in the etiology and molecular mechanisms of conditions such as schizophrenia, bipolar disorder, major depressive disorder, Alzheimer's disease, and Parkinson's disease. These findings suggest that circRNAs may provide a novel framework contributing to the molecular dysfunctions underpinning these complex neurological conditions.

Molecular Psychiatry; <https://doi.org/10.1038/s41380-025-02925-1>

INTRODUCTION

Unravelling the intricate genetic mechanisms underlying non-coding RNA (ncRNA) biology has emerged as a promising frontier for the development of new therapeutic and diagnostic tools for neurological conditions. ncRNAs have gained significant attention as evidence accumulates regarding their biochemical functionality, which was once underestimated [1–5]. Approximately 80% of the human non-coding transcriptome is now predicted to be biochemically active [1, 3, 6, 7]. A notable class of ncRNA are circular RNAs (circRNAs) [8–14]. CircRNAs are highly stable, covalently closed-looped, non-linear RNAs generated by circularizing back splicing events. Most circRNAs are derived from exonic regions of protein-coding genes [8, 13]. Multiple circRNA isoforms can arise from a single gene, depending on splicing processes involved, with circRNAs transcribed from combinations of exons, introns, intergenic, and untranslated regions [8, 13, 15]. These transcripts are often co-transcriptionally generated with pre-mRNA on the same strand and are known to compete with mRNA for expression levels [9, 16]. While the majority of circRNAs are derived from the nuclear genome, a subset has been identified originating from the mitochondrial chromosome [17, 18].

Since circRNAs were first identified in 1976, they were largely dismissed as “junk RNA”, with only a few being recognized as

biochemically functional, primarily in the context of viral biology [19–21]. However, over the past decade, circRNAs have become an area of high-impact research, with many circRNA transcripts identified across species, from archaea to humans [22–24]. Many circRNAs have high sequence conservation across different species, and over 150,000 unique human circRNAs have been computationally identified, with a subset experimentally validated. CircRNAs are expressed throughout the human body, displaying cell-type and tissue-specific expression patterns. For example, distinct profiles have been observed in neuronal cells such as dopaminergic neurons, pyramidal neurons, and glia [25–27]. Furthermore, circRNAs are predominantly expressed in the mammalian brain at levels significantly higher than those in other tissues [26, 28, 29]. The temporal expression of circRNAs appears to be dynamic during early neuronal development and shows increased levels with age [30–32]. Dysregulated circRNA expression has been reported across various neurological conditions, often linked to altered physiological processes and functional differences [27, 33–37]. In this review, we focus on five conditions – schizophrenia, bipolar disorder, major depressive disorder, Alzheimer's disease, and Parkinson's disease – highlighting key findings from human and rodent studies to explore recent discoveries in circRNA biology and their relevance to neurological disorders.

¹Institute for Biomedicine and Glycomics, Griffith University, Brisbane, QLD, Australia. ✉email: a.cristino@griffith.edu.au

Received: 19 July 2024 Revised: 11 January 2025 Accepted: 10 February 2025

Published online: 17 February 2025

New advancements in molecular biology and computer science have shed light on what was once considered a “junk” portion of the genome. A wide range of ncRNAs has now been shown to possess biochemical functionality, playing critical roles in cellular processes such as transcriptional regulation [38, 39], post-transcript processing [10, 14], protein expression [40–42], and splicing regulation [9, 43]. While the full extent of their impact on brain activity remains to be elucidated, ncRNAs, including circRNAs, are proving to be invaluable tools for understanding the etiology and pathophysiology of neurological conditions, as well as potential candidates for clinical applications.

THE MOLECULAR PROPERTIES OF CIRCRNAs

The precise mechanisms of the biogenesis, transport, localization and degradation of circRNAs remain largely unresolved. However, current research indicates that human circRNAs are predominantly composed of exonic regions (~60%), with most circRNAs consisting entirely of protein-coding exons. Exonic circRNAs originate from pre-mRNAs that first undergo canonical splicing followed by backsplicing, and most are generated co-transcriptionally in a spliceosome-dependent manner [44, 45]. Typically, these circRNAs consist of two or three exons, with intervening introns excised during the splicing process [46]. In addition to exonic circRNAs, they can also arise from other genomic regions, including intronic-exonic, fully intronic, and intergenic regions [47–49]. Beyond biogenesis, circRNA functions are influenced by several molecular properties, including subcellular transport and localization, degradation pathways, and protein translation capacity, which are discussed in the following sections.

Biogenesis

Several distinct mechanisms contribute to circRNA biogenesis (Fig. 1A). Most circRNAs are generated through a process called backsplicing, where the canonical 5' and 3' splice sites of a pre-mRNA are joined in reverse orientation, forming a covalent 3–5' phosphodiester bond [13, 50]. This process is tightly regulated by trans-acting factors such as RNA binding proteins (RBPs), including QKI (QKI, KH Domain Containing RNA Binding) [51] and NOVA2 (NOVA Alternative Splicing Regulator 2) [52], which dimerize, causing increased proximity of splice sites through specific motifs within the upstream and downstream intronic regions. Cis-acting elements also play critical role in circRNA formation, for example, flanking intronic base-pairing of reverse complementary sequences (e.g. *Alu* elements [12]) located near the splice sites can pair with one another, facilitating circRNA biogenesis through a mechanism similar to the interaction between RBPs.

Adenosine deaminases acting on RNA (ADARs) play an important role in circRNA biogenesis by editing RNA through adenosine to inosine (A-to-I) conversions. This editing is guided by the base-pairing of reverse complementary sequences, which modulates the stability of RNA secondary structures. By altering these structures, ADARs regulate the accessibility of regulatory RBPs, thereby either reducing or enhancing back-splicing events [53, 54]. In addition, the spliceosome machinery is thought to directly participate in circRNA formation, akin to canonical splicing, although the precise mechanisms remain to be fully elucidated [9, 13, 50]. In the intron lariat-driven circularization model, an internal backsplicing event occurs after exon skipping, producing a mRNA that lacks the skipped exons and a circRNA can be formed if the lariat structure escapes debranching. Sequence elements such as a 7-nucleotide GU motif and an 11-nucleotide C-rich sequence near the 5' splice sites protect the lariat from degradation by debranching enzymes (e.g. Debranching RNA Lariats 1, DBR1), promoting circRNA formation [47, 55]. Moreover, N⁶-methyladenosine (m⁶A) RNA modification, which are known to regulate various aspects of RNA metabolism, including splicing,

stability, and translation, have also been implicated in circRNA biogenesis. Specifically, m⁶A-modified exons located near the start and stop codons of mRNAs can undergo backsplicing mediated by the nuclear m⁶A reader protein YTHDC1 (YTH N6-Methyladenosine RNA Binding Protein C1) [56–58].

Subcellular transport and localization

Since circRNAs are generated in the nucleus and found across various subcellular compartments, with exon-containing circRNAs predominantly localized in the cytoplasm [12, 59, 60], their nuclear export is likely to follow a tightly regulated process. Multiple mechanisms involving RBPs, export receptors, and RNA helicases facilitate circRNA nuclear export (Fig. 1B). The primary mechanism of circRNA nuclear export relies on Ran-GTP binding export receptors [61, 62] which transport circRNAs through the nuclear pore complex. In mammals, exportin-2 (XPO2) plays a key role, exporting approximately 80% of the most abundantly expressed circRNAs [62]. Another important exportin, exportin-4 (XPO4), is responsible for transporting a distinct subset of exonic circRNAs, which are highly expressed in brain tissues [61].

In addition to Ran-GTP-dependent exportins, length-dependent mechanisms involving RNA helicases have been identified. DDX39A (DEX-Box Helicase 39 A) and DDX39B (DEX-Box Helicase 39 B) are required for the export of short (less than 700nt) and long circRNAs (greater than 800nt), respectively. This length-dependent export mechanism has been observed across metazoans, suggesting it is evolutionarily conserved [63, 64]. Interestingly, canonical mRNA export factors, such as NXF1 (Nuclear Export Factor 1), ALYREF (ALY/REF Export Factor), and GANP (Germinal Center-Associated Nuclear Protein), have minimal involvement in circRNA export [62]. This highlights the distinct nature of circRNA export pathways, which are mechanistically different from those of linear RNAs. Nonetheless, the NXF1-NXT1 pathway, a known mRNA export system, has been implicated in transporting GC-rich intronic circRNAs, demonstrating the diversity and complexity of circRNA export mechanisms [65].

Moreover, RNA methylation, particularly N6-methyladenosine (m⁶A), plays an important role in circRNA export. The nuclear protein YTHDC1, which also participates in the m⁶A-dependent biogenesis of specific circRNA subsets [56–58], mediates the export of m⁶A-modified circRNAs, including circNSUN2 [66] and circRNA3634 [67]. However, not all m⁶A-modified circRNAs rely on YTHDC1 for export. For instance, circ-ZNF609 biogenesis is reduced following YTHDC1 knockdown, but its export and stability remain unaffected [57], indicating the involvement of alternative mechanisms in the export of m⁶A-modified circRNAs.

CircRNAs have also been identified in exosomes [68–73], a class of extracellular vesicles that originate from intraluminal vesicles within multivesicular endosomes. Exosomes play key roles in intercellular communication, often transporting RNAs, proteins and lipids [74, 75]. Interestingly, circRNAs are enriched in exosomes relative to their abundance in the cells of origin, indicating selective transport into exosomes [69]. Although research on exosomal circRNAs is still emerging, most evidence so far comes from studies in cancer and immunology. Several possible mechanisms have been proposed for the selective packaging of circRNAs into exosomes, such as RBP recognition of specific binding sequences [76–78] resembling the selective export of small RNAs [79–81]. Other potential mechanisms involve long non-coding RNAs (lncRNAs) [82], microRNAs (miRNAs) [69], or circRNAs [70] size as determinants of selective transport. However, the exact pathways by which circRNAs are selectively transported into exosomes remains unclear.

Despite the progress made in understanding circRNA transport and subcellular localization, many questions remain to be resolved. The involvement of additional RNA export-related factors is still unclear, and it is likely that future research will identify new pathways or proteins contributing to the transport of specific




Fig. 1 CircRNA biogenesis, molecular properties, and degradation pathways. **(A)** CircRNA biogenesis is predominantly explained by two proposed models: (1) direct backsplicing, facilitated by binding sites recognized by RNA binding proteins (RBPs) or inverted repeat elements that bring splice sites into close proximity; and (2) the lariat-driven circularization model, where exon skipping generates a lariat structure that is subsequently processed into an intron-driven circularization. BSS backsplicing sites. **(B)** The nuclear export of circRNAs is dependent on their length, methylation status, sequence origin, and interactions with nuclear proteins. Transport into extracellular spaces is mediated by selective exosomal transport, which may operate through mechanisms unique to circRNAs, distinct from those of other cellular components. **(C)** CircRNA degradation involves several pathways, including those mediated by RNA interference (RNAi), endoribonucleases (RNases), and structural features of circRNAs.

circRNA subsets. Furthermore, specialized transport mechanism or tissue-specific factors may play essential roles in organs such as the brain, where circRNAs are highly expressed and found in neurites and synaptosomes [29, 83, 84].

Stability and degradation

The covalently closed-loop structure of circRNAs, which lacks free 5' and 3' ends, makes them significantly more stable and resistant to degradation by exonucleases compared to their linear counterparts [85]. In mammalian cells, most circRNAs have a half-life of 18.8–23.7 h, making them stable for at least 2.5 times longer than linear RNAs, which have a half-life of 4.0–7.4 h [86]. This extended half-life suggests that the circRNA decay machinery differs substantially from that of linear RNA, with several molecular properties affecting circRNA stability and degradation, including endonuclease activity mediated by miRNA binding, secondary structure, RNA-DNA duplexes, and m⁶A modification (Fig. 1C).

CircRNAs can be degraded through endonucleases via RNA interference (RNAi) pathways. The Argonaute-2 (AGO2) endonuclease, guided by miRNA, has been implicated in circRNA degradation. For instance, miR-1224 binds to the precursor circRNA-*flip11* in the nucleus of mice spinal cord neurons, reducing circRNA-*flip11* expression in an AGO2-dependent manner [87]. Another example is miR-671, which directs AGO2-mediated cleavage of the circular transcript from the *long intergenic non-protein coding RNA 632* gene (circLINC00632 also known as circCDR1a) [88], a process that plays an important role

in brain function [89]. Additionally, GW182 (Trinucleotide Repeat Containing Adaptor 6 A, TNRC6A), a key component of the RNAi pathway, is involved in the degradation of circRNAs via RNAi machinery-independent pathways [90].

Highly structured circRNAs can be degraded by RBP complexes. For example, the UPF1 RNA helicase unwinds circRNA secondary structures, enabling degradation by the endonuclease G3BP1 (G3BP Stress Granule Assembly Factor 1) [91]. Some circRNAs, such as *ci-ankrd52*, can form DNA:RNA hybrids at their transcription sites which maintains an open secondary structure forming a stable R-loop with the template DNA that is recognized and degraded by RNase H1 [92]. Moreover, during viral infections, circRNAs forming 16–26 bp RNA duplexes can be cleaved by RNase L, an endonuclease activated in response to viral infection. This degradation is necessary to activate PKR, a double stranded RNA-activated protein kinase, which limits viral and host protein synthesis [93–95]. CircRNAs with m⁶A modifications are targeted for degradation by the RNase-P/MRP complex. This process requires HRSP12 (Reactive Intermediate Imine Deaminase A Homolog, RIDA), which acts as a bridge between the m⁶A reader protein YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein F2) and RNase-P/MRP, facilitating the rapid decay of m⁶A-modified circRNAs [96, 97].

Currently, there is no evidence for a canonical degradation pathway specific to circRNAs. The available research suggests that multiple cellular pathways, some of which are shared with linear RNAs, contribute to circRNA degradation. However, the relative




Fig. 2 Diagram summarizing mechanisms of actions and functions of circRNAs. (A) One of the most extensively studied functions of circRNAs is miRNA sponging, where circRNAs bind to complementary miRNA binding sites, sequestering miRNAs and reducing their inhibitory effect on target mRNAs. (B) CircRNAs can encode functional peptides through m^7G cap-independent translation mechanisms, facilitated by internal ribosome entry sites (IRES) or N6-methyladenosine (m6A) modifications. (C) CircRNAs regulate transcription by interacting with transcriptional factors or spliceosome components. (D) Many circRNAs contain binding sites for RNA binding proteins (RBPs), regulating the localization, stability, or activity of these proteins. (E) CircRNAs can act as scaffolds in protein-protein interactions, binding to multiple proteins simultaneously to facilitate their functional interplay. (F) CircRNAs are often co-transcriptionally produced with mRNAs from the same host gene, competing with linear transcripts for splicing events, thereby interfering with the expression of their cognate mRNAs.

importance of these pathways and whether novel mechanisms exclusive to circRNAs exist, remain to be fully elucidated. Further research is needed to uncover the dominant mechanisms underlying circRNA stability and decay.

THE MECHANISMS OF ACTION OF CIRC RNAs microRNA sponge

MiRNA sponging is a well-known function of circRNA (Fig. 2A), in which circRNAs sequester miRNAs through complementary binding sequences, reducing their bioavailability. This sponging activity inhibits miRNA-mediated gene silencing by preventing miRNAs from binding to their target mRNA transcripts. Typically, miRNAs form complexes with AGO2, and their seed region (a conserved 2–8 nucleotide sequence) binds to the 3' UTRs of mRNAs, leading to degradation of mRNA transcripts containing complementary miRNA response elements [98, 99].

One of the most prominent examples of miRNA sponging is circCDR1as, which contains over 60 conserved binding sites for miR-7 [100, 101]. This large number of binding sites and high expression relative to most circRNAs, enables circCDR1as to tightly regulate miR-7 availability, potentially affecting the expression of several target genes. Dysregulation of miR-7 has been shown to impair the development and function of the brain and pancreas [102, 103] and is also implicated in Parkinson's disease through dysregulation of α -synuclein expression [104]. In line with this, abnormal expression of circCDR1as has been found to play important roles in brain development [101], insulin production and secretion [39], as well as in promoting cell proliferation and metastasis in cancers such as nasopharyngeal carcinoma [105], osteosarcoma [106], and melanoma [107].

Several other instances of miRNA sponging have been identified, suggesting that circRNAs may act as miRNA decoys, representing a key regulatory mechanism. For example, the testis-specific circRNA sex-determining region Y (circSry) functions as a

sponge for miR-138, though the functional impact remains to be determined [100]. CircNRIP1 acts as a decoy for miR-149, and is transmitted between gastric cancer cells via exosomes, where it affects the AKT1/mTOR pathway to promote tumor metastasis [108]. In bladder cancer, circHIPK3 contains two binding sites for miR-558, where sponging of miR-558 suppresses heparinase (HPSE) expression [109].

As research into circRNA sponging continues to grow, it is becoming increasingly evident that this mechanism plays a crucial role in cancer and stem cell biology [110, 111]. However, much remains to be uncovered, particularly in the context of brain development, neurological function and diseases.

Protein translation

In eukaryotes, mRNA translation typically depends on chemical modifications at both the 5' and 3' ends of linear RNAs, which enhance stability, facilitate transport, and promote protein synthesis. The 5' end is capped with a methylated guanosine (m^7G), connected to the mRNA via a 5'-5' triphosphate bridge, while the 3' end is polyadenylated, forming a poly(A) tail required for efficient protein translation [112–114]. However, some mRNAs can undergo cap-independent translation via internal ribosome entry sites (IRES), enabling protein synthesis without the need for a 5' cap and 3' poly(A) tail [115]. Given their covalently closed-loops structure, circRNAs lack 5' and 3' ends, making cap-independent translation the only feasible mechanism (Fig. 2B).

Nearly four decades ago, circRNA translation was first observed in the human hepatitis delta virus, where a circRNA containing an open reading frame (ORF) with start and stop codons directed the synthesis of a 215-amino-acid protein [116]. Subsequent studies in the mouse testis-determining gene *Sry* provided further evidence of circRNA translation [117]. Later research demonstrated that synthetic circRNA with an IRES can indeed be translated in vitro [118]. More recently, naturally occurring circRNA translation has been confirmed in vivo [119–121]. Systematic approaches

combining polysome profiling, non-poly(A)-selected RNA sequencing, and bioinformatics revealed robust evidence of endogenous circRNA translation in human cells [122–124].

Several cap-independent mechanisms have been identified for circRNA translation, including IRES-dependent [122–125], short IRES-like A/U-rich sequences [126], m6A IRES (MIREs)-dependent [127, 128], and rolling circle translation (RCA)-dependent translation [119]. However, the precise mechanisms by which ribosomal subunits and translation initiation factors assemble during circRNA cap-independent translation remains unclear. Recent studies suggest that combinatorial interactions between different RBPs and components of the eIF4 and eIF3 complexes are crucial for the regulation of cap-independent translation [127–131].

Our current understanding of the abundance and functional roles of circRNA-derived proteins remains limited, but emerging evidence indicates that these circRNA-derived proteins play key roles in normal development and may be implicated in various diseases. For instance, in fruit flies, a circRNA from the *muscleblind* locus (circMbl) generates a peptide under starvation conditions, which localizes to synaptosome fractions in fly heads. The absence of identifiable peptide signal sequences in the proteins encoded by both the Mbl mRNA and circMbl suggests that translation may occur locally at the synapses [124]. Another fruit fly circRNA, derived from the *sulfateless* (*sfl*) gene (circSfl), produces a small protein regulated by insulin-mediated lifespan extension and aging, potentially linking circSfl-derived protein to lifespan regulation [132].

In humans, a circRNA derived from the amyloid β precursor protein (*APP*) gene, known as circA β -a, can be translated into a novel A β -containing polypeptide in the brains of both Alzheimer's disease patients and non-dementia individuals. While no evidence currently links the circA β -a-derived protein to dementia, this discovery suggests an alternative pathway for A β biogenesis, which could help explain sporadic cases of the disease [126]. Other circRNA-derived proteins have primarily been associated with cancers [122–124, 127, 133]. Given that approximately 24% of mammalian circRNAs contain 3' and/or 5' UTRs [59], it is likely that many circRNA-derived proteins will be identified in future studies.

Transcriptional regulation

CircRNAs can regulate gene transcription through various mechanisms. Some circRNAs interact directly with components of the RNA Polymerase II (Pol II) complex, acting as either positive or negative transcriptional regulators (Fig. 2C). For instance, a recent study demonstrated that metal-responsive element-containing circRNAs inhibit the transcription of copper stress-responsive genes by blocking the recruitment of gawky, a chromatin-interacting RBP, to active chromatin regions. This blockage leads to aberrant cytoplasmic accumulation of gawky, thus disrupting gene transcription [134].

Certain nuclear intronic circRNAs, such as ci-ankrd52, accumulate at their transcription sites, where they serve as positive regulators of their parental gene by association with Pol II complex [47]. Similarly, exon-intron circRNAs like circEIF3J and circPAIP2 have been shown to regulate Pol II transcription by forming RNA-RNA interactions with U1 small nuclear ribonucleoprotein (U1 snRNP), thereby modulating the transcription of their parental genes [38]. Another example is circHuR, which represses transcription of its parental gene, *human antigen R* (*HuR*), by directly interacting with CCHC-type zinc finger nucleic acid binding protein (CNBP). This interaction prevents CNBP from binding to the *HuR* promoter, consequently suppressing *HuR* transcription and inhibiting gastric cancer progression [135].

CircRNAs can also activate parental gene transcription through mechanisms involving intronic enhancers [136] or promoter methylation [137]. For example, in fruit flies, a maternally inherited intronic circRNA (*sisR-4*) activates an enhancer located within the intron of its parental *deadpan* (*dpn*) gene, which is essential for the

regulation of zygotic gene expression during embryogenesis [136]. Similarly, a *FLI1* exonic circRNA (FECR1) binds to the *FLI1* promoter and recruits TET1 (Tet Methylcytosine Dioxygenase 1) to induce DNA demethylation at a CpG island in the *FLI1* promoter. This epigenetic modification enables *FLI1* to drive metastasis in breast cancer by leveraging both canonical oncogenic pathways and epigenetic regulation via FECR1 [137]. In addition to their nuclear roles in transcriptional regulation, several cytoplasmic circRNAs have been found to regulate the expression of transcription factors primarily by sponging miRNAs that target specific transcription factors [138–140].

RNA binding protein transport, scaffold, and decoy

Several studies suggest that a subset of circRNAs may play critical roles in transporting RBPs to specific subcellular locations, facilitating the assembly of protein-RNA and enzyme-substrate complexes, as well as acting as protein decoys or sponges (Fig. 2D). These mechanisms are closely linked to various aspects of circRNA biogenesis, localization, stability and degradation [50, 51, 141, 142]. CircRNAs can act as mediators in biochemical pathways, selectively transporting, scaffolding, or sponging molecules, thus forming complex regulatory networks (Fig. 2E). These overlapping mechanisms converge to produce context-specific functional outputs in diverse cellular processes.

For example, in colorectal cancer, the upregulation of circYAP1 is linked to a reduction in immune activation against cancer cells. CircYAP1 binds directly to the YAP1 (yes1 associated transcriptional regulator) protein, preventing its phosphorylation which enhances YAP1 nuclear import, where interactions with transcription factor 4 (TCF4) promotes the expression of the immune checkpoint inhibitor PD-L1 (CD274), leading to immune evasion and tumor progression [143]. Similarly, circAMOTL1, which is highly expressed in neonatal human cardiac tissue, promotes AKT-mediated cardiomyocyte survival and repair. Research indicates that circAMOTL1 binds to both PDK1 (pyruvate dehydrogenase kinase 1) and AKT1 (AKT serine/threonine kinase 1), enhancing AKT1 phosphorylation and facilitating the nuclear translocation of pAKT1, thereby promoting cardioprotective effects [144]. In glioblastoma, reduced miRNA abundance compared to normal brain tissue has been associated with an aberrant nuclear localization of DICER1 (dicer 1 ribonuclease III, a crucial endonuclease for miRNA maturation). This mislocalization could be mediated by its interaction with RNA Binding Motif Protein 3 (RBM3) and circ2082, one of the most upregulated circRNAs in glioblastoma cells [145].

CircRNAs also act as scaffolds or recruiters to modulate protein degradation. In hepatocellular carcinoma, circPABPC1 directly links integrin subunit beta 1 (ITGB1) to the 26S proteasome for degradation in a ubiquitination-independent manner [146]. In breast carcinoma, circDNMT1 expression is increased and binds to the RBP AUF1 (HNRNPD, heterogeneous nuclear ribonucleoprotein D) and the transcription factor TP53 (tumor protein P53), promoting nuclear translocation of both proteins, which enhances cell proliferation and inhibits of senescence [147]. In non-cancer mouse cells, circFoxo3 binds to the cell cycle-associated proteins CDK2 (cyclin dependent kinase 2) and p21 (CDKN1A, cyclin dependent kinase inhibitor 1A), reducing the formation of cyclin E/CDK2 complexes, thereby blocking the G1 to S phase transition in the cell cycle [148].

Competition between linear and circular RNA expression

CircRNAs are co-transcriptionally produced with their cognate mRNAs and can act as transcript regulators affecting the expression of their linear counterparts (Fig. 2F). Investigations into this competitive dynamic have revealed that the balance between circular and linear RNA production can significantly impact gene expression and function. One notable example involves circMbl and its cognate mRNA. The biogenesis of circMbl

is tightly regulated by a splicing factor encoded by the *muscleblind* (*Mbl*) gene that binds to specific sites in the flanking introns of circMbl. This interaction establishes a feedback loop, as circMbl directly binds to MBL protein, modulating its availability and consequently controlling its own production. This mechanism exemplifies how circRNA can act as a regulator of its associated splicing factor, maintaining cellular homeostasis [9].

Recent findings have introduced a novel mechanism by which circRNAs can regulate mRNA stability. CircRNAs that bind both the exon junction complex (EJC) and the 3' UTR of mRNAs have been shown to induce degradation of the bound mRNA. This process resembles the canonical nonsense-mediated decay (NMD) and relies on EJC binding downstream of termination codons and NMD factors such as PNRC2 (Proline Rich Nuclear Receptor Coactivator 2), UPF1 (UPF1 RNA Helicase and ATPase) and UPF2 (UPF2 Regulator of Nonsense Mediated mRNA Decay). In the circRNA-mediated pathway, circRNAs tethered to the 3' UTR bring EJCs into proximity, facilitating mRNA degradation through an NMD-like mechanism. The efficiency of this process depends on the number and location of circRNA-mRNA binding sites, illustrating the complexity of circRNA-mediated regulation [149].

Another interesting case is circHOMER1, which has strong sequence complementarity to the 3' UTR of HOMER1B mRNA isoform. Reduced expression of circHOMER1 has been linked to increased HOMER1B expression, suggesting a regulatory interplay between circular and cognate linear RNA. The RBP ELAVL4 binds to sites near the complementary regions on both the circHOMER1 and the HOMER1B 3' UTR, suggesting the role of circHOMER1 in regulating linear HOMER1B expression [150].

COMPUTATIONAL IDENTIFICATION OF CIRC RNAs

Recent advances in understanding circRNA biogenesis and their roles in various pathological and physiological contexts have driven the development of bioinformatic tools for circRNAs analysis [43, 151]. Over three million unique circRNA transcripts across multiple species have been catalogued, with online databases such as circBase [152], circBank [153], CIRCpediav2 [154], and circAtlas3 [155], available for reporting and comparison. These resources provide comprehensive information including associated studies, cell types, chromosome coordinates, predicted splice sites, RNA-binding proteins sites, and miRNA binding sites. Specialized resources like NeuroCirc, which focuses on circRNAs in the human brain [156], are particularly useful for researchers studying neuronal tissues.

The main strategy for identifying circRNAs from short-read RNA sequencing data relies on detecting backsplice junctions (BSJs). Given that circRNAs lack a poly(A) tail, cDNA library preparation methods must avoid poly(A) selection. Instead, these methods typically involve ribosomal RNA depletion followed by cDNA synthesis that captures both coding and non-coding RNAs, including circRNA molecules. To date, all computational tools for circRNA identification rely on initial experimental evidence from RNA-seq data, with fully de novo computational methods based solely on genomic features yet to be developed. Current computational approaches to circRNA identification are divided into two main strategies: pseudo-reference-based and chimeric-read-based [157, 158].

Pseudo-reference-based methods use existing gene annotation data to create BSJ references, which can limit discovery in less-studied cell types or species. Notable pseudo-reference-based tools include Circall [159], NCLscan [160], and KNIFE [161]. For example, Circall [159] implements a two-step pseudo-reference approach: it first maps RNA-seq reads to an annotated reference transcriptome to remove linear RNA reads, then aligns the remaining unmapped reads to a BSJ reference database. This database is constructed from annotated RNA sequences, creating pseudo-sequences for circRNAs and their tandem counterparts by

combining sequences from constituent exons. To reduce false positives, Circall applies a two-dimensional local false discovery rate (2dFDR) method [162], which accounts for both BSJ-supporting reads and circRNA length. Chimeric-read-based methods align sequencing reads directly to a reference genome, using noncolinear or chimeric reads to detect BSJs. For instance, circRNA_finder [11] utilizes the chimeric alignment output from STAR program [163] to identify chimeric junctions on the same chromosome flanked by canonical donor-acceptor splice sites (GT—AG). Other chimeric alignment tools include CIRI2 [164], DCC [165] and CIRCexplorer3 [166]. In the case of CIRI2 [164], it reports BSJ mapped reads from alignments using BWA-MEM program [167].

There is currently no single “gold standard” toolkit for circRNA identification [168, 169], and combining multiple detection methods often enhances accuracy. A notable evaluation of 16 circRNA detection tools identified over 3,15,000 unique circRNAs, with 1516 validated experimentally by RT-qPCR, demonstrating the value of a consensus approach [169]. Examples of multi-tool platforms include SRCP [170], CirComPara2 [171] and nf-core/circRNA [172]. Long-read sequencing platforms, such as Oxford Nanopore Technology, have recently advanced circRNA identification [173] by enabling full circRNA transcript coverage and detection of isoforms [174] as well as native RNA modifications [175]. Unlike short-read sequencing, which limits full transcript identification and quantification, long-read sequencing technologies provide a clearer picture of co-regulated transcripts and insights into splicing processes [176].

To investigate miRNA sponging potential, traditional miRNA target prediction tools like miRanda [177], TargetScan [178], and RNAhybrid [179] have been repurposed for circRNA-miRNA interaction prediction [41, 155, 180]. For circRNA-RBP interaction prediction, tools like catRAPID omics v2.0 integrate experimentally validated RNA-binding proteins using motifs collected from multiple databases [181]. Additional resources for circRNA-RBP interaction prediction include CircSSNN [182], CRAFT [183], CircInteractome [41], CircSite [184], and circAtlas [155]. For predicting the protein-coding potential of circRNAs, CircProPlus employs unsupervised learning algorithm and logistic regression model based on open reading frame (ORF) characteristics such as ORF size and coverage [185]. Other useful tools include cirCodAn [186], C2CDB [187], CRAFT [183] and circRNADb [188]. Visualization tools such as CIRI-vis [189] and circView [190] further support the analysis of splicing patterns, regulatory elements, and miRNA/RBP binding sites, advancing our understanding of circRNA functionality and complexity.

EXPERIMENTAL VALIDATION AND CHARACTERIZATION OF CIRC RNAs

Identifying circRNAs in RNA-seq data is a valuable initial step in selecting candidates for further experimental validation and characterization. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) remains one of the most widely used methods for analyzing circRNA candidates [169, 191–193]. This approach uses divergent primers specifically designed to amplify BSJs with primer design principles akin to mRNAs, however it is also essential to know the candidate BSJ sequence and its flanking regions. Tools such as circPrimer2 [194] and CircInteractome [41] assist with primer design for known BSJs. For novel circRNA candidates not catalogued in public databases, general-purpose tools like Primer3 [195] can be used by providing a sequence spanning the BSJ to generate divergent primers and predict amplicon sizes. Sanger sequencing also serves to confirm backsplice junctions via PCR with divergent primers targeting candidate circRNAs [196, 197].

Northern blotting is a commonly used method for circRNA validation. Probes are designed to target BSJs via hybridization

with complementary RNA sequences that are separated by size in an electrophoresis assay [29, 45, 46, 85, 100, 101]. Additionally, treatment with the 3–5′ exonuclease RNase R can enrich circRNA levels by selectively digesting linear RNAs, which is beneficial prior to RNA-seq, qRT-PCR, and northern blot experiments, as circRNAs are often expressed at low levels [10, 193, 198]. Nonetheless, highly structured regions in linear RNA may block RNase R digestion, potentially confounding this interpretation [198].

Given that circRNAs are often significantly less abundant than their linear cognate RNAs, determining their subcellular localization is crucial for understanding their potential function [94, 199]. The quantification of circRNAs by qRT-PCR in different cellular fractions such as the nucleus [47], ribosomes [199], mitochondria [17], and exosomes [69, 70] can reveal clues about their roles, providing hypotheses for further characterization. However, subcellular fractionation techniques may suffer from purity issues and potential contamination. RNA fluorescence in situ hybridization (FISH) using antisense probes targeting the BSJs offers a more precise method for single-cell localization. Despite the high accuracy, detecting circRNAs by FISH can be challenging due to their low abundance, complex secondary structures, or protein interactions at the BSJ. Once circRNAs are validated and their subcellular localization determined, appropriate experimental approaches can be selected for further characterization. For instance, nuclear circRNAs are most likely almost all non-protein-coding and may serve regulatory roles, cytoplasmic circRNAs have been shown to function as miRNA sponges, RBP transporters, or scaffolds while ribosome-associated circRNAs may indicate potential translation into peptides.

To further investigate the functional role of circRNAs, modulation of their expression through knockdown, knockout or over-expression assays provides valuable functional information. Specifically, for loss-of-function studies, circRNAs can be knocked down via small hairpin RNA (shRNA), small interfering RNA (siRNA) [200, 201], or CRISPR-Cas13 [199, 202] targeting the BSJs. Yet, effective circRNA depletion without disrupting their linear RNA counterparts remains a major challenge, as circRNAs are predominantly derived from protein-coding genes. In cases where circRNAs lack a cognate linear RNA [89], are formed by intronic complementary sequences [85, 203, 204] or specific RBP binding sites, knockout approaches may be more feasible. CircRNA overexpression can also elucidate their functional roles, via strategies such as expression vector construction with circRNA-producing exons and their flanking introns [46, 70, 100, 205, 206] or transfecting cells with synthetic circRNAs generated through *in vitro* transcription and circularization [207–209]. A thorough discussion of all available validation and characterization methods and their limitations is beyond the scope of this review; therefore, we recommend several comprehensive studies for greater comprehension [8, 210, 211].

CIRC RNAs IN THE BRAIN AND NEUROLOGICAL CONDITIONS

The current literature extensively demonstrates new mechanisms and functional roles of circRNAs in cancer biology. However, evidence regarding the mechanism of circRNAs in specific brain cells and human neurological disorders remains limited. Nevertheless, compelling findings highlight the critical importance of RNA splicing in brain development and disease [212, 213], with growing research suggesting circRNAs as an essential regulatory layer in neuronal tissue and associated disorders [26, 28, 29, 83, 84, 214]. Studies have consistently shown that circRNA expression levels in the brain are significantly higher than in other tissues, a pattern observed across various species, including humans [29], mice [84], rats [215], and fruit flies [11].

CircRNAs are not only highly abundant in the brain [28, 29, 156, 216] but also present a dynamic range of expression across cell types, development stages, and aging [11, 26, 215, 217].

In neurons, genes encoding synaptic proteins tend to produce more circRNAs, many of which are enriched in the synaptosome, suggesting potential roles in neuronal differentiation, synaptic function, and plasticity [26, 83, 84, 218]. CircRNAs accumulate in the central nervous system with age [11, 32, 215, 217, 219], potentially contributing to cell senescence and age-related neurological disorders [32, 217, 219]. Dysregulation of circRNA expression and function has been implicated in several neurological disorders, with much of this research emerging over the past decade [26, 214, 220–223]. Despite these advances, the precise roles of circRNAs in the pathology of neuropsychiatric and neurodegeneration disorders remain poorly understood.

This review focuses on three neuropsychiatric disorders (schizophrenia, bipolar disorder, and major depressive disorder) and two neurodegenerative diseases (Alzheimer's disease and Parkinson's disease), summarizing what is currently known about circRNAs in these conditions. Table 1 presents a concise overview of key findings with some experimental evidence provided in relevant published studies on human circRNAs, which are further explored in the following sections.

Schizophrenia

Schizophrenia is a complex polygenic neurological disorders characterized by a spectrum of symptoms [224, 225]. The disorder typically manifests between the ages of 16 and 30, with an earlier onset and higher prevalence in males compared to females [224, 226, 227]. Symptoms include hallucinations, delusions, impaired emotional expression, and disorganized speech [224, 227, 228]. A recent genome-wide association study (GWAS) identified 287 genomic loci associated with schizophrenia with at least 600 genes potentially implicated in schizophrenia [229], in which the majority of genetic variants occurred in non-coding regulatory regions of the genome [229, 230], highlighting the importance of the non-coding genome in understanding complex disorders like schizophrenia. Investigating the role of circRNAs in schizophrenia offers a promising perspective on how non-coding RNAs may contribute to disease pathophysiology [26, 231]. Although the research field is still in its early stages, studies have reported altered circRNA expression in both peripheral blood samples [232–235] and postmortem brain tissues [223, 236, 237] from schizophrenia patients.

CircRNAs in blood cells are particularly intriguing as potential biomarkers or therapeutic targets; For example, one study found 22 differentially expressed circRNAs, with 14 downregulated and 8 upregulated in disease [234]. Another study reported 13 downregulated circRNAs compared to healthy controls [235]. In early-onset schizophrenia patients, circRNA expression was dramatically reduced, with 234 downregulated circRNAs and one upregulated [232]. Conversely, a smaller cohort study reported 392 upregulated and 58 downregulated circRNAs in schizophrenia patients compared to controls [233]. There is no overlap for genes reported in these studies which underscores the challenges of biomarker discovery in schizophrenia.

In postmortem brain tissue, particularly the dorsolateral prefrontal cortex (DLPFC), circRNA expression is significantly reduced in schizophrenia patients compared to controls. A recent study identified 574 differentially expressed circRNAs, with 184 upregulated and 390 downregulated [236]. The authors proposed that schizophrenia involves dysregulated circRNA biogenesis, characterized by a global reduction in circRNA levels in patients' brains. Another study found 203 differentially expressed circRNAs in the DLPFC of patients, of which 182 (90%) were downregulated [237]. These findings support the hypothesis proposed by Mahmoudi et al. [236]. This reduction may increase the bioavailability of miRNAs, amplifying their inhibitory effects on target mRNAs and dysregulating protein expression (Fig. 3A). Two key RBPs involved in circRNA biogenesis, ADAR1 and QKI, exhibit distinct expression patterns in schizophrenia patients [238, 239],

Table 1. Summary of select studies describing dysregulated circRNAs in neurological disorders including schizophrenia (SCZ), bipolar disorder (BD), major depressive disorder (MDD), Alzheimer's disease (AD), and Parkinson disease (PD).

Condition	circBase ID	CircRNA parent gene symbols	Source	Sample size	Methods	Overall dysregulation of circRNAs and/or key finding	Ref
SCZ	hsa_circ_0000638	ETFA	Plasma	8 CON 10 SCZ	RNAseq	1 upregulated 234 downregulated	[232]
	hsa_circ_0005035	IGFR1					
	hsa_circ_0001200	PTTGIP					
	hsa_circ_0001789	RAB1FIP1					
	hsa_circ_0007762	STXBP5					
hsa_circ_0005035	IGF1R						
SCZ	hsa_circ_0003999	MPND	Blood	3 CON 3 SCZ	RNAseq RT-qPCR	392 upregulated 58 downregulated	[233]
	hsa_circ_0030042	FOXO1					
SCZ/BD	hsa_circ_0005813	LONP2	Blood	20 CON 19 BP 20 BD	RNAseq	7 upregulated in BD vs CON 26 downregulated in BD vs CON 8 upregulated in SCZ vs CON 14 downregulated in SCZ vs CON	[234]
	hsa_circ_0001307	RAD54L2					
	hsa_circ_0080653	NGF1C					
	hsa_circ_0099001	SCARNA10					
	hsa_circ_0003290	TMEM2					
	--	EZH1					
hsa_circ_0000914	FKBP8						
hsa_circ_0001550	RARS						
SCZ	hsa_circ_0039066	PRR14	Blood	50 CON 50 SCZ	RNAseq	13 downregulated	[235]
SCZ	hsa_circ_0141293	LONP2	DLPFC	20 CON 20 SCZ	RNAseq RT-qPCR	184 upregulated 390 downregulated	[236]
	hsa_circ_0002672	RABGAP1					
	hsa_circ_0112551	GPR137B					
	hsa_circ_0002602	PPP2CA					
	hsa_circ_0073237	VCAN					
	hsa_circ_0115215	TOP1					
	hsa_circ_0002506	MYO9A					
	hsa_circ_0000023	HPTBP3					
	hsa_circ_0002799	ZNF236					
	hsa_circ_0084780	STAU2					
	hsa_circ_0141280	SV2B					
	hsa_circ_0142301	STXBP5					
	hsa_circ_0104963	IGF1R					
hsa_circ_0007178	BRAF						
SCZ	hsa_circ_0120251	NRXN1	DLPFC	178 CON 171 SCZ	RNAseq	182 downregulated 10 upregulated	[237]
	hsa_circ_0137107	STAU2					
	--	SV2B					
	hsa_circ_0130962	STXBP5					
	hsa_circ_0005035	IGF1R					
hsa_circ_0006961	BRAF						
hsa_circ_0007661	RABGAP1						
BD/SCZ	hsa_circ_0006916	HOMER1	OFC	34 CON 34 SCZ 32 BD	Microarray RT-qPCR	38 dysregulated in BD vs CON 34 dysregulated in SCZ vs CON	[223]
	hsa_circ_0030788	NALCN					

Table 1. continued

Condition	circBase ID	CircRNA parent gene symbols	Source	Sample size	Methods	Overall dysregulation of circRNAs and/or key finding	Ref
BD	-- hsa_circ_0141109	Chr7:141760111-141786128 DLEU2	Blood	20 CON 20 BD	RNAseq RT-qPCR	44 downregulated 50 upregulated	[253]
	-- hsa_circ_0128413 hsa_circ_0100444	Chr6:29945234-30009177 chr19:54726815-54784154 SGCD LOC100616668					
BD	hsa_circ_0056537	CCNT2	ACC; B-LCL	27 CON 24 BD 12 CON 19 BD	RNAseq RT-qPCR	26 dysregulated, and circCCNT2 is associated with bipolar disorder and lithium treatment	[254]
MDD	--	DYM	Plasma	32 CON 49 MDD	RT-qPCR	CircDYM could be a potential biomarker for MDD diagnosis as well as determination of transcranial magnetic stimulation effectiveness in treating MDD	[221]
MDD	hsa_circ_0015067	PBX1	Venous blood	6 CON 6 MDD	RNAseq	Intersection of homologous circRNAs between human GSE182193 dataset and CUMS mouse model: 14 upregulated 1 downregulated	[262]
MDD	--	DYM	Serum	30 CON 50 MDD	RT-qPCR	CircDYM could be a potential therapeutic for treating MDD through microglial functional modulation through circDYM-mir9-HECTD1/HSP90 axis.	[266]
AD	-- -- -- --	HOMER1 KCNK2 ICAT1 FMN1	Parietal cortex; IFG; APC; STG; Perirhinal cortex	13 CON 83 AD 195 samples (40 controls,89 definite AD,31 probable AD, and 35 possible AD)	RNAseq RT-qPCR	236 significant ADAD-associated circRNAs	[278]
AD	hsa_circ_0003391	UBASH3B	Plasma; Blood	50 CON 50 AD 20 Dementia with Lewy Bodies 40 Vascular Dementia	Microarray RT-qPCR	High positive correlation between multiple AD clinical traits and circUBASH3B expression	[282]
AD	hsa_circ_0020462 hsa_circ_0139156 -- hsa_circ_0135879 hsa_circ_0127616 hsa_circ_0110235 hsa_circ_0006852	DOCK1 NTRK2 DLG1 TRAPPC9 APC KIF1B CORO1C	Frontal lobe; Hippocampus; Temporal Cortex; Plasma	222 CON 213 AD	RNAseq	Using six different publicly available datasets of RNA sequencing data, a select grouping of circRNAs were dysregulated among AD individuals across different brain regions along with plasma samples, some which had high genes implicated in AD pathophysiology	[283]
AD	hsa_circ_0001481 hsa_circ_0001819	EMB UBR5	Blood	17 CON 11 aMCI 22 SCD 5 AD	Microarray RT-qPCR Luciferase assay	Potential biomarkers identified for early detection of AD from blood	[284]

Table 1. continued

Condition	circBase ID	CircRNA parent gene symbols	Source	Sample size	Methods	Overall dysregulation of circRNAs and/or key finding	Ref
AD	hsa_circ_0014353	<u>RPS27</u>	Blood	139 CON 143 AD 50 VaD 51 PDD 52 bvFTD 50 DLB	RNAseq	A panel of six circRNAs were developed from a combination of three datasets to measure blood derived circRNAs for diagnosis of AD and correctly differentiate from other dementia types.	[285]
	hsa_circ_0014356	<u>RPS27</u>					
	hsa_circ_0074533	<u>RPS14</u>					
	hsa_circ_0077001	<u>EEF1A1</u>					
	hsa_circ_0022417	<u>FTH1</u>					
	hsa_circ_0089894	<u>TMSB4X</u>					
AD	hsa_circ_0050263	<u>ATP13A1</u>	Blood	29 CON 26 AD 5 MCI	Microarray RT-qPCR	Five significantly dysregulated circRNAs were validated and had good diagnostic accuracy for distinguishing AD.	[286]
	--	<u>BRAF</u>					
	hsa_circ_000302	<u>PTRM1</u>					
	--	<u>TADA2A</u>					
	--	<u>NOL10</u>					
AD	--	<u>HOMER1</u>	Frontal lobe; Temporal lobe	20 CON 19 AD	RNAseq Proteomics Synaptosome confocal microscopy	circRNA mislocalization in AD pathophysiology demonstrated by enrichment of circRNAs at synapses	[287]
	--	<u>GSK3β</u>					
	--	<u>GSK3β</u>					
AD	hsa_circ_0006916	<u>HOMER1</u>	APC; STL; PHG; IFG		RNAseq	Across all clinical dementia rating stages at FDR of greater than or equal to 0.05 in all four brain regions, 147 dysregulated circRNAs were identified, with only 4 dysregulated in all four brain regions	[288]
	hsa_circ_0073128	<u>HOMER1</u>					
	hsa_circ_0000437	<u>CORO1C</u>					
	hsa_circ_0127664	<u>KCNN2</u>					
	hsa_circ_0006837	<u>REER</u>					
	hsa_circ_0127521	<u>MAN2A1</u>					
	hsa_circ_0073127	<u>HOMER1</u>					
	hsa_circ_0005494	<u>ATP13A3</u>					
AD	hsa_circ_0001911	<u>FANCB</u>	DLPFC	8 CON 9 AD	RNAseq	120 upregulated 1325 downregulated	[289]
	hsa_circ_0117996	<u>FASTKD1</u>					
	hsa_circ_0008521	<u>PSEN1</u>					
	hsa_circ_0008521	<u>PSEN1</u>					
AD	hsa_circ_0008521	<u>PSEN1</u>	Entorhinal cortex; Hippocampus Postcentral gyrus; SFG	54 AD 62 AD 68 AD 69 AD	Microarray	CircRNAs derived from PSEN1 were shown to have predictive influences on molecular mechanisms of AD progression	[290]
	hsa_circ_0003848	<u>PSEN1</u>					
AD	hsa_circ_0008521	<u>PSEN1</u>	Parietal cortex; Frontal pole; STG; PHG; IFG	23 CON 21 ADAD 253 AD	RNAseq	Higher circPSEN1 expression is specific to ADAD and independent of mutation	[294]
	hsa_circ_0003848	<u>PSEN1</u>					
PD	hsa_circ_0001776	<u>ESYT2</u>	Blood	PPMI 161 CON 259 PD ICICLE- 48 CON 48 PD	RNAseq	Three significant circRNAs in PPMI and not statistically significant differentially expressed circRNAs after correction in ICICLE-PD but replication of the direction of 7 previously found significant circRNAs were identified.	[305]
	hsa_circ_0000944	<u>CCDC9</u>					
	hsa_circ_0002627	<u>BMS1P1</u>					
	hsa_circ_0142640	<u>INTS6L</u>					
	hsa_circ_0004368	<u>REPS1</u>					
	hsa_circ_0001187	<u>DOPIB</u>					
	hsa_circ_0004833	<u>AR6IP1</u>					
	hsa_circ_0000497	<u>SLAIN1</u>					
	hsa_circ_0000069	<u>STIL</u>					
	hsa_circ_0000994	<u>SLC8A1</u>					

Table 1. continued

Condition	circBase ID	CircRNA parent gene symbols	Source	Sample size	Methods	Overall dysregulation of circRNAs and/or key finding	Ref
PD	hsa_circ_0065842	GNAI2	Plasma	3 CON 9 PD	RNAseq	1005 downregulated	[306]
	hsa_circ_0067965	FNDC3B					
	hsa_circ_0131191	chr6:158675463-					
	hsa_circ_0085965	158675686					
	hsa_circ_0138219	SHARPIN					
	hsa_circ_0093281	VAV2					
	hsa_circ_0034762	chr10:20571145-					
	hsa_circ_0037165	20571330					
	hsa_circ_0041511	MAPKBP1					
	hsa_circ_0115568	MRPL28					
		ZZEFT					
		chr20:62034919-62035057					
	PD	--					
--		ITGAX					
--		SPI1					
--		NCF1					
--		PADI4					
--		ETFA					
--		ESYT2					
--		FAM13B					
--		RNF13					
--		CCDC91					
--		SUZ12					
--		CSEL1					
--		SHOC2					
PD	hsa_circ_0000061	SCHM1	Exosomes	15 CON 23 PD	RNAseq RT-qPCR	circSCMH1 expression had strong correlation between MDS-UPDRS III scores in PD patients and could potentially regulate ARID1A and C1orf115 function.	[308]
	hsa_circ_0003258	ZNF652					
PD	--	HBB	Blood	4 CON 4 PD	RNAseq	282 downregulated 129 upregulated	[309]
	hsa_circ_0036353	SIN3A					
	hsa_circ_0000690	ITGAL					
	hsa_circ_0001535	FAM13B					
	hsa_circ_0001451	FBXW7					
	hsa_circ_0004870	RBM39					
	hsa_circ_0000605	SLTM					
	hsa_circ_0014606	YY1API					
	hsa_circ_0001801	PCMTD1					
	hsa_circ_0001772	RBM33					
	hsa_circ_0000497	SLAIN1					
PD	hsa_circ_0001187	DOPIB	Blood	60 CON 60 PD	RT-qPCR	6 downregulated	[310]
	hsa_circ_0004368	REPS1					
	hsa_circ_0001566	MAPK9					
	hsa_circ_0003848	PSEN1					
	hsa_circ_0006916	HOMER1					
	hsa_circ_0127305	SNCA					
PD	hsa_circ_0127305	SNCA	MPP ⁺ -induced PD cell models	--	RT-qPCR Dual luciferase assay MTT assay	CircSNCA indirectly regulates miR-7 and SNCA	[311]

Table 1. continued

Condition	circBase ID	CircRNA parent gene symbols	Source	Sample size	Methods	Overall dysregulation of circRNAs and/or key finding	Ref
PD	hsa_circ_0000994	SLC8A1	Amygdala; MTG; Substantia nigra	27 CON 42 PD	RNAseq RT-qPCR	Significant difference in substantia nigra of PD and control, with circSLC8A1 upregulated in this region in PD and having potential sponging of miR-128. CircRNA expression in brain regions studied found to be inversely proportional to RNA editing levels	[313]
PD	hsa_circ_0060180	DLGAP4	MPP ⁺ -induced PD cell models	--	Cell assays Luciferase assay RT-qPCR	CircDLGAP4 attenuated effects of MPP ⁺ neurotoxin in SH-SY5Y and MN9D treated cells.	[314]
PD	hsa_circ_0004846	SAMD4A	MPP ⁺ -induced PD cell models	--	Cell assays Luciferase assay RT-qPCR	CircSAM4A regulates miR-29c-3p and knockdown of this circRNA induces protective effect on MPP treated SH-SYBY cells	[315]
PD	--	BACH1 GDI2 TMEM138 EPS15 JA423830 LINC012333	Blood	40 CON 40 PD	RNAseq	circEPS15 is a predicted target for PD treatment	[317]
PD	hsa_circ_0000284	HIPK3	Serum; CSF	95 CON 92 PD	RT-qPCR RNA IP assay Luciferase assay	circHIPK3 sponges miR-124 which disrupts STAT3/NALP3 pathway in PD leading to neuroinflammation	[319]
PD	hsa_circ_0054220	LOC728730	MPP ⁺ -induced PD cell model	--	Cell assays Luciferase assay RT-qPCR	Inhibition of circLOC728730 suppressed apoptosis in MPP treated cells and was found to bind to two miRNAs (miR-145 and miR-625) which regulates HMGA1	[320]
PD	hsa_circ_0007021	HIVEP2	MPP ⁺ -induced PD cell model; Venous blood	85 CON 127 PD	Cell assays Luciferase assay RT-qPCR	Increasing circHIVEP2 attenuates MPP induced inflammation and apoptosis. CircHIVEP2 was also found to bind miR-485-3p which when increased had similar effect to increasing circHIVEP2 but exact mechanism of action unknown.	[321]
PD	hsa_circ_0004381 hsa_circ_0017204 hsa_circ_0085869 hsa_circ_0090668	ARID1B TCNOS12_00002816 FAM83H HUWE1	Plasma	100 CON 300 PD	Microarray RT-qPCR	A small panel of circRNAs could predict early onset PD and distinguish late PD from early	[322]

circBase IDs [152] are provided when reported in the original study. RNA source encompasses cell-types or tissue used for identification of circRNAs. Differentially expressed circRNAs are indicated by their host gene symbol: downregulated circRNAs are shown in underlined red, while upregulated circRNAs are shown in slanted blue. CON controls, *DLPFC* dorsolateral prefrontal cortex, *OFC* orbital frontal cortex, *ACC* anterior cingulate cortex, *IFG* inferior frontal gyrus, *APFC* anterior prefrontal cortex, *STG* superior temporal gyrus, *PHC* parahippocampal cortex, *MTG* medial temporal gyrus, *STL* superior temporal lobe, *CSF* cerebrospinal fluid, *B-LCL* B lymphoblastoid cell line.




Fig. 3 Dysregulated circRNAs may disrupt different mechanisms associated with disease. (A) Dysregulated circRNA biogenesis in schizophrenia may arise from altered regulation of RBPs due to schizophrenia-associated genetic variants in intronic regions, affecting circRNA expression and downstream miRNA-mediated gene regulation. (B) Reduced CircNRXN1 expression may disrupt synapse formation and transmission through several potential mechanisms, including impairments in RBPs or mRNA transport/scaffolding, altered miRNA sponging, peptide translation, or modifications in intercellular communication by exosomes. However, these hypotheses remain to be tested. (C) Reduced circHOMER1 expression in bipolar disorder is linked to loss of cognitive flexibility through a complex network of interactions affecting glutamatergic synaptic transmission. A similar mechanism may also play a role in schizophrenia and other neurological disorders. (D) In major depressive disorder, reduced circDYM expression increases miR-9 bioavailability, leading to downregulation of HECTD1. This, in turn, inhibits HSP90 ubiquitination, resulting in microglial activation and enhanced inflammation by pro-inflammatory cytokines. (E) Reduced circHOMER1 expression in Alzheimer's disease patients is proposed to increase miR-651 bioavailability, leading to inhibition of PSEN1 and PSEN2 expression. This dysregulation may contribute to amyloid plaque accumulation and neurodegeneration. (F) Increased circCORO1C expression in Alzheimer's disease patients reduces miR-105 bioavailability, resulting in upregulation of APP expression and contributing to amyloid plaque formation and neurodegeneration. (G) CircA β , derived from the APP gene, can be translated into peptide sequences that may contribute to accumulation of amyloid plaque accumulation and neurodegeneration in Alzheimer's diseases. However, the mechanism by which these circRNA-derived peptides are exported and their contribution to amyloid plaque formation and dementia remains unclear. IRES internal ribosome entry site. (H) Increased expression of circPANK1 and circSNCA in the substantia nigra of Parkinson's disease patients is associated with their function as miR-7 sponges. This increases SNCA (α -synuclein) expression, promoting the formation of neurotoxic aggregates in dopaminergic neurons.

suggesting their potential involvement in impaired circRNA production. Additionally, schizophrenia-associated genetic variants in intronic regions may disrupt canonical splicing sites or complementary sequences required to form secondary structures in intronic stem-loops, which are critical for circRNA circularization [240]. Despite these findings, the precise mechanisms underlying this disruption in circRNA biogenesis and its downstream functional consequences contributing to disease remains largely unknown.

In reviewing the published data [236, 237], it was revealed that circRNAs derived from 32 genes were consistently reduced in

DLPFC of schizophrenia patients. These circRNAs are derived from genes implicated in key neuronal processes, such as synapse assembly and transmission (*NRXN1*, *STAU2*, *SV2B*), synaptic vesicle exocytosis (*SV2B*, *STXBP5*), axon regeneration (*BRAF*, *IGF1R*), and insulin-like receptor signaling pathway (*RABGAP1*, *IGF1R*). The reduced levels of circRNAs decrease their miRNA sponging efficiency, in turn increasing bioavailable miRNAs that more effectively bind to target mRNAs, thereby repressing protein expression of genes involved in multiple biological pathways. Beyond serving as miRNA decoys, dysregulated circRNAs in schizophrenia may disrupt additional cellular processes, such as

subcellular localization and transport of RBPs, potentially impairing neuronal differentiation and synaptic function. Furthermore, some circRNAs may encode peptides with unknown functions, adding further complexity to their contribution to schizophrenia risk. These disruptions, resulting from altered circRNA expression, likely contribute to broader functional impairments in neuronal processes that are central to the pathophysiology of schizophrenia.

The *neurexin 1* (*NRXN1*) gene encodes a presynaptic cell adhesion protein that interacts with a diverse repertoire of postsynaptic proteins, playing essential role in the assembly and maturation of synapses [241]. *NRXN1* encodes two main isoforms with several alternative splicing specifying different properties of synapses [242]. Several studies have identified recurrent structural genetic variations within the *NRXN1* locus in schizophrenia patients, including intronic deletions and other mutations [243–245]. These genetic variations may disrupt sequence patterns recognized by RBPs like QKI or ADARs, potentially changing the kinetics of circRNA and mRNA production. Thus, the dysfunctions associated with *NRXN1* mutations in schizophrenia may also extend to the regulatory roles of *NRXN1* circRNAs, further contributing to dysregulation of synapse formation and transmission (Fig. 3B). Interestingly, the *insulin-like growth factor 1 receptor* (*IGF1R*) gene encodes a tyrosine kinase activated by a hormone called IGF1 similar in chemical structure to insulin. IGF1R circRNAs were also found to be reduced in the peripheral blood of schizophrenia patients [232], suggesting its potential as blood-based marker with similar expression profile in brain tissue. IGF1R mRNA was found to be reduced in brain tissue from subventricular zone of schizophrenia patients potentially impairing the ability of neural stem and neuronal progenitor cells to respond to IGF1 during neurogenesis [246].

A recent study identified reduced expression of a circRNA derived from *HOMER1* gene (circHOMER1) in the DLPFC of patients with schizophrenia and bipolar disorder [223]. In this study, circRNAs were detected and quantified using a circRNA microarray panel containing 13,617 probes targeting backsplice junctions, designed based on multiple RNA-seq datasets. CircHOMER1 was prioritized for functional validation in mouse models and human neuronal cultures derived from patient-induced pluripotent stem cells (iPSCs). In these iPSC-derived neuronal cultures, circHOMER1 expression was consistently reduced. Functional studies in mouse models revealed that circHOMER1 competes with the *HOMER1B* mRNA isoform, which encodes a protein essential for synaptic plasticity and glutamate neurotransmission. The *HOMER1B* protein interacts with Group1 metabotropic glutamate receptors (GRM5) and anchoring proteins such as SHANK2 (SH3 and multiple ankyrin repeat domains 2) to regulate calcium signaling in excitatory synapses via N-Methyl-D-aspartate receptors (NMDAR) [247, 248]. Additionally, circHOMER1 was shown to directly interact with the 3'UTRs of *HOMER1B* isoform, as well as with ELAVL4, an RBP predominantly expressed in differentiated neurons. ELAVL4 is crucial for the transport and synaptic localization of circHOMER1 [150, 223] (Fig. 3C). Notably, circHOMER1 expression was consistently reduced in the DLPFC and orbitofrontal cortex (OFC) of bipolar disorder patients, suggesting potential shared mechanisms between schizophrenia and bipolar disorder. Its functional roles are further discussed in the following section, focusing on insights derived from mouse and human stem-cell-based assays.

Bipolar disorder

Bipolar disorder (BD) is a highly heritable and complex polygenic condition characterized by diverse symptoms, including mania, depression, and hypomania. The intricate nature of bipolar disorder represents a significant challenge for the development of appropriate molecular and genetic models [249–251]. A recent GWAS involving 41,917 BD cases and 371,549 controls identified

64 loci associated with the disorder [252]. As with other GWAS findings, most identified SNPs are in non-coding regions (94%), with a substantial proportion in intronic regions (64%), which may influence the regulation of circRNA expression [252]. These regulatory SNPs could potentially lead to the gain or loss of circRNA function by affecting their biogenesis or interactions with mRNAs.

A recent study reported 33 differentially expressed circRNAs (26 downregulated and 7 upregulated) in the peripheral blood cells of 19 BD patients compared to 20 unaffected controls [234]. Another study identified 94 differentially expressed circRNAs (44 downregulated and 50 upregulated) in the peripheral blood cells of 20 patients compared to 20 unaffected controls [253]. However, direct comparisons between these studies are limited, as the latter study did not include a summary table detailing the differential expression of circRNAs and their corresponding host gene annotations. A meta-analysis integrating these datasets could provide a more robust understanding of circRNA dysregulation in bipolar disorder.

Several studies have reported differences in circRNA expression profiles in the prefrontal cortex regions of bipolar disorder patients, including DLPFC, OFC [223], anterior cingulate cortex (ACC) [254] and medial frontal gyrus (MFG) [255]. These regions play critical roles in cognitive, emotional, and executive functions. Even subtle dysfunctions in these interconnected neuronal networks can disrupt their coordinated activity, contributing to the development of mental health disorders. Comparing these studies, 45 genes produce circRNAs dysregulated in at least two brain regions. Interestingly, one gene, *NALCN* (*sodium leak channel, non-selective*), was found to express a circRNA dysregulated in different brain regions and cohorts, albeit with discordant direction (downregulated in OFC [223] and upregulated in MFG [255]). *NALCN* is a voltage-gated ion channel responsible for the regulation of Na⁺ permeability to control neuronal excitability [256]. However, the functional role of circNALCN in the nervous system and its association with BD remains unknown.

Of particular interest is a circRNA derived from the *HOMER1* gene, circHOMER1, which is consistently downregulated in the DLPFC and OFC of BD patients [223]. Genetic variation in the *HOMER1* locus near a distal enhancer region (rs6865469, $p = 1.65e-08$) is significantly associated with bipolar disorder [252]. How this variation in the *HOMER1* regulatory region affects circRNA biogenesis remains unclear. Human stem cell-based assays with CRISPR knock-in and knockout approaches to generate stem cell lines with different allelic combinations could help elucidate the effect of these genotypes on circRNA expression. CircHOMER1 is also reduced in iPSC-derived neuronal cultures from BD patients. In vivo knockdown of circHOMER1 in the OFC of mice alters the expression of the *HOMER1B* mRNA isoform and numerous alternative transcripts from genes involved in synaptic plasticity and psychiatric disorders [223].

Bipolar disorder patients often struggle with adapting their behavior to changing circumstances, a deficit perceived as impaired cognitive flexibility. In mice, reduced circHOMER1 expression in the OFC impairs behavioral flexibility, as demonstrated in a reversal learning test [150]. The mechanism of action for circHOMER1 in both schizophrenia and bipolar disorder appears to involve its direct interaction with the 3' UTR of *HOMER1B* mRNA and the sequestration of ELAVL4, an RBP required for *HOMER1B* expression in the synapses (Fig. 3C). The regulation of RNA processing into linear and circular RNA isoforms depends on the profile of RBPs expressed in each brain regions and cell type, as well as the genetic variations associated with each disorder, potentially underlying the disease-specific patterns of coding and non-coding RNA signatures.

Another study identified circCCNT2 upregulated in the ACC of 13 BP patients when compared to 13 neurotypical controls, a finding replicated in an independent cohort of 24 patients and 27

controls [254]. The *CCNT2* (cyclin T2) gene encodes a cyclin protein that regulates CDK9 (cyclin dependent kinase 9) activity, promoting the phosphorylation of RNA polymerase II and other transcription factors [257]. Bioinformatic predictions suggest that circCCNT2 may interact with over 25 RBPs and potentially serve as a sponge for miR-877-5p, which is predicted to target genes involved in synapse formation. However, these hypotheses require experimental validation. Interestingly, circCCNT2 expression is reduced in B lymphoblastoid cells from patients following lithium treatment, whereas no change is observed in unaffected controls [257]. The authors propose circCCNT2 as a potential alternative treatment target for patients who experience adverse effects or do not respond to lithium therapy [254]. Although preliminary, these findings provide compelling evidence for circCCNT2's role in BD and its potential utility in developing novel therapeutic approaches

Major depressive disorder

Approximately one in five individuals will be affected by major depressive disorder (MDD) during their lifetime [258, 259]. MDD has a heritable component, with up to 37% of the risk explained by genetic variation across at least 44 risk loci [260], however it is more likely to result from a combination of environmental and genetic factors. High comorbidity with other psychiatric disorders as well as differences in personality, sex, and age, also contribute to the risk of developing MDD [261]. Due to the intricate interplay between genes, environmental factors, and the limited understanding of the underlying molecular mechanisms, treatment for MDD is often suboptimal. This underscores the need to explore all potential avenues, including the contribution of both protein-coding and non-coding genes, to identify gene networks and molecular mechanisms associated with the disorder. While some studies suggest that circRNAs may play a role in MDD, the evidence remains limited, though some investigations have started to uncover their potential involvement in the disease pathology [220, 221, 262–265].

A recent study suggests that a circular RNA derived from exons 4, 5 and 6 of the *DYM* (*dymeclin*) gene (circDYM) could serve as a novel therapeutic target for MDD [266]. CircDYM was found to be downregulated in the peripheral blood of MDD patients, as well as in the plasma and hippocampus of two depressive-like mouse models. Overexpression of circDYM in mice ameliorated depressive-like symptoms, indicating its potential therapeutic relevance. The study reveals that circDYM functions as a sponge for miR-9, regulating downstream miR-9 target genes, including *HECTD1* (HECT domain E3 ubiquitin protein ligase). Reduced circDYM expression leads to increased bioavailability of miR-9, resulting in the downregulation of *HECTD1*. This, in turn, reduces HSP90 ubiquitination, which promotes microglial activation and enhances neuroinflammation. Further supporting these findings, previous studies have demonstrated increased miR-9 expression in the nucleus accumbens and striatum of a depressive-like mouse model [267, 268]. Additionally, neurons exporting miR-9-containing exosomes that promote M1 polarization in microglia, leads to the release of proinflammatory cytokines [269]. These findings highlight a potential mechanism by which circDYM downregulation exacerbates neuroinflammation by increasing miR-9 activity, leading to dysregulation of microglial function (Fig. 3D).

Recent investigations have revealed changes in circRNA expression in depressive-like animal models following treatment with antidepressant compounds, including traditional Chinese medicine [270] and plant-derived therapies [262]. One study demonstrated alterations in circRNA expression profiles in a depressive-like rat model treated with Xiaoyaosan (XYS), a traditional Chinese medicine formula with known antidepressant effects. Rats exhibiting depression-like behaviors and treated with XYS showed differential expression of 28 circRNAs [270]. XYS

treatment improved depression symptoms by increasing locomotor activity and sucrose preference while reducing immobility time during forced swimming tests. Additionally, XYS attenuated synaptic loss in the hippocampus, potentially through modulation of the PI3K/Akt signaling pathways, a well-established target of conventional antidepressants. However, the identities of affected circRNAs and the precise mechanisms by which XYS influences their expression remain largely unknown [270].

In another study, a depressive-like mouse model was treated with geniposide (GP), a plant-derived compound. GP restored the expression of circ_0008405 (homolog of circPBX1), a circRNA that was downregulated in depressive-like mice, leading to amelioration of depression-like symptoms. Circ_0008405 acts as a miRNA sponge for miR-25-3p, increasing the expression of its target genes, including *Gata2* [262]. Interestingly, a previous study found that overexpression of human *GATA1* and *GATA2* induced depressive behavior in rats [271]. These findings suggest that dysregulation of circRNA expression, such as the reduction of circ_0008405, contributes to depressive-like behaviors. Treatment with GP not only normalized circRNA expression but also ameliorated depression-like symptoms, highlighting the therapeutic potential of targeting circRNA networks to treat depression.

Alzheimer's disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the aggregation of hyperphosphorylated tau protein into intracellular neurofibrillary tangles and amyloid beta (A β) peptide into extracellular plaques. These pathological changes lead to memory loss, cognitive decline, and impairment in executive functions [272, 273]. AD is a complex multifactorial condition with a broad spectrum of manifestations, ranging from early-onset cases – frequently associated with rare autosomal dominant mutations in *APP* (*amyloid beta precursor protein*), *PSEN1* (*presenilin 1*) and *PSEN2* (*presenilin 2*) genes – to late-onset sporadic cases, which are associated with common alleles of small effect sizes that in aggregation contribute to genetic susceptibility to AD [274, 275]. Dysregulated ncRNAs, including circRNAs, have been implicated in the regulation of amyloid plaque formation and progression, playing critical roles in AD pathophysiology [276, 277]. These findings suggest that circRNAs may influence key molecular pathways underlying AD, providing opportunities for therapeutic intervention. Numerous studies have also highlighted the role of circRNAs in the etiology and severity of AD [126, 278–281], and some circRNAs have been proposed as potential biomarkers for diagnosing and monitoring the progression of AD in studies using peripheral blood cells, plasma, and cerebrospinal fluid [282–286].

A meta-analysis has provided an atlas of circRNA expression changes in cortical regions of AD patients, revealing significant correlations with clinical and neuropathological traits of AD [278]. This analysis identified 164 circRNAs dysregulated in the brains of AD patients, several of which are co-expressed with AD-associated genes involved in brain hypometabolism and clinical traits. In particular, circHOMER1 is significantly downregulated in AD patients and strongly correlates with disease severity as indicated by the clinical dementia rating and Braak score – a measure of AD severity based on distribution and density of neurofibrillary tau tangles in the brain. Furthermore, circHOMER1 contains multiple putative binding sites for miR-651, a miRNA predicted to target key AD-associated genes, including *PSEN1* and *PSEN2* [278]. Reduced circHOMER1 expression increases miR-651 bioavailability, enhancing miRNA-mediated suppression of *PSEN1* and *PSEN2*, potentially impairing γ -secretase activity, which is essential for amyloid beta processing (Fig. 3E). In contrast, circCORO1C is upregulated in AD patients and associated with clinical traits and AD-associated genes including *APP*. Acting as a sponge for miR-105, circCORO1C reduces miR-105 bioavailability, leading to increased *APP* expression, which may exacerbate amyloid plaque

formation and synaptic dysfunction (Fig. 3F). These findings are supported by independent studies and illustrate the potential regulatory roles of circHOMER1 [287–289] and circCORO1C [283, 288] in AD pathogenesis.

A circRNA derived from the APP gene (circA β) has been identified in the prefrontal cortex of AD patients [126]. CircA β encodes a novel 175-amino acid amyloid beta polypeptide, which can be processed into amyloid beta peptides, suggesting an alternative pathway for amyloid beta biogenesis (Fig. 3G). Another circRNA, circPSEN1, is upregulated in AD patients [290] and is proposed to act as a sponge for miR-4668-5p and miR-5584-5p. These miRNAs regulate genes involved in TGF- β 1 and Notch signaling pathways, which are critical to AD progression [291–293]. Interestingly, autosomal dominant AD studies have revealed circPSEN1 isoform dysregulation without changes in PSEN1 mRNA expression [294].

Overexpression of circRIMS2 in the hippocampus of an AD mouse model caused a reduction in dendritic spine density and memory deficits [281]. Amyloid β was found to enhance METTL3-dependent m6A modification of circRIMS2, increasing its stability and promoting more efficient sponging of miR-3968. Mir-3968 is known to inhibit *UBE2K* (*ubiquitin conjugating enzyme E2 K*) expression, which can alter synaptic transmission via ubiquitination of GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) protein. Increased circRIMS2 expression resulted in more *UBE2K* activity, leading to increased ubiquitination and degradation of GRIN2B protein, causing synaptic dysfunction [281, 295, 296]. Co-overexpression of miR-3968 and circRIMS2 in mouse model restored dendritic spine density and memory performance to healthy-like levels. Interestingly, RIMS2 mRNA levels were consistently downregulated in the hippocampus of AD patients across multiple independent studies [297–299], suggesting AD-specific splicing disruptions at the *RIMS2* locus [300]. Aberrant splicing, possibly caused by a 5' splice site variant, has been implicated in exon skipping and nonsense-mediated mRNA decay [301]. These findings highlight the multifaceted impact of circRIMS2 dysregulation on synaptic function and its potential role in AD pathophysiology.

Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder globally, with its prevalence increasing significantly with age. The disease manifests with a combination of motor symptoms, including tremors, bradykinesia, and rigidity, and non-motor symptoms, such as cognitive impairment, sleep disturbances, and autonomic dysfunction. PD is typically characterized by the progressive loss of dopaminergic neurons in the substantia nigra and the accumulation of protein aggregates containing α -synuclein [302, 303]. A large-scale multi-ancestry meta-analysis of GWASs identified 78 independent risk loci associated with PD, with the majority of genetic variations (95%) occurring in regulatory non-coding regions [304]. Notably, this includes variations in genes expressing circRNAs, such as the *alpha-synuclein* (*SNCA*) gene, which plays a central role in PD pathogenesis. Emerging evidence suggests that circRNAs may serve as biomarkers for diagnosis and assessment of PD severity [305–310]. Furthermore, other studies have investigated the involvement of circRNAs in key pathogenic mechanisms, including their regulation of α -synuclein aggregation, neuroinflammation, apoptosis, autophagy, and mitochondrial dysfunction, with much of this research conducted using animal and cell models of PD [27, 311–321].

A study involving 300 PD patients and 100 healthy controls identified circulating cell-free circRNA as potential plasma biomarkers for PD [322]. Two diagnostic panels were developed: one consisting of two circRNAs (circARID1B and circTCONS_I2_00002816) demonstrated high sensitivity and specificity for early diagnosis of PD, while a second panel, comprising

four circRNAs (circFAM83H, circHUWE1, circARID1B and circTCONS_I2_00002816), was able to differentiate late-stage from early-stage PD [322]. Another novel biomarker and potential therapeutic target for PD, circEps15, was recently identified in both human and animal studies [317]. This circRNA was found to be downregulated in the plasma of PD patients and significantly correlated with disease progression. Consistent with patient findings, reduced circEps15 expression was observed in plasma and midbrain samples from a chemically induced mouse model of PD. Overexpression of circEps15 in these mice and SH-SY5Y cells was found to promote dopaminergic recovery in vitro through improved mitochondrial function. Mechanistically, circEps15 functions as a miR-24 sponge promoting stable expression of target gene *PINK1* thus enhancing PINK1-PRKN-dependent mitophagy to eliminate damaged mitochondria and maintain mitochondrial homeostasis in neurons [317].

A study reveals that circRNAs tend to accumulate in an age-dependent manner in several brain regions in healthy individuals but in PD patients this correlation is lost in substantia nigra where total number of circRNAs is reduced [313]. In contrast, the same study reports that circSLC8A1 increases in the substantia nigra of PD patients and in cultured cells exposed to oxidative stress induced by Paraquat. CircSLC8A1 carries several binding sites for miR-128 and identified to interact with AGO2. This strongly suggests this circRNA functions as a sponge affecting the expression of miR-128 target genes. However, the exact functional impact caused by miR-128 sponging remains unknown.

Other studies in animal and cell line models identified several dysregulated circRNAs, such as circSNCA [311], circPANK1 [316], circHIPK3 [319], circHIVEP2 [321], circDLGAP4 [314] and circSAM4A [315]. All these circRNA are proposed to function as miRNA sponges affecting biological pathways associated with PD such as α -synuclein aggregation, neuroinflammation and degeneration, and mitochondrial dysfunction. Notably, circPANK1 and circSNCA are proposed to function as miR-7 sponges and found upregulated in PD mouse and cell models. One such cell model using SH-SY5Y cells treated with a neurotoxin (1-Methyl-4-phenylpyridinium) found increased circSNCA expression [311]. CircPANK1 was found to be upregulated in the substantia nigra of a PD mouse model treated with rotenone, another compound used to mimic key pathological traits of disease [316]. Increased expression of these two circRNAs upregulates α -synuclein SNCA protein expression by reducing miR-7 bioavailability and enhancing the expression of target genes, such as *SNCA*, thus increasing risk of SNCA aggregation and neurodegeneration of dopaminergic neurons [311, 316] (Fig. 3H).

POTENTIAL CLINICAL APPLICATIONS OF CIRC RNAs

The stability, specificity, and abundance of circRNAs render them as not only potentially diagnostic tools but also as novel therapeutic targets. The aberrant expression and resulting dysregulation in normal functioning of circRNAs in neurological conditions is becoming a more prominent area of research, with fascinating discoveries being made. In the last two decades, new insights have been made into circRNA and their interplay with regulatory mechanisms that underpin complex and typically highly polygenic neurological conditions such as schizophrenia, bipolar disorder, depression and as well as neurodegenerative conditions like Alzheimer's disease and Parkinson's disease. One of the most compelling aspects of circRNAs for studying neurological conditions lies in their abundant expression in the brain [29, 59], where they are highly expressed in neuronal cells comparatively to other cell types, as well as other cell-type specific expression patterns [25]. CircRNAs are also highly stable, have unique transcript sections across backsplice junction region, and tend to have low immunogenicity, all of which are features that can aid in developing more robust RNA based therapeutics [13, 209, 233].

As detecting circRNAs has become more streamlined, plasma derived circRNAs have also shown promise for developing diagnostic biomarkers and panels dedicated for early detection and monitoring of neurological conditions [221, 322–324]. The versatility of circRNAs as biomarkers in neurological conditions is underscored by their presence in cerebrospinal fluid, offering a valuable diagnostic window into central nervous system milieu [324, 325]. New possibilities for leveraging circRNAs as potential biomarkers in neurological conditions are also being determined in urine and saliva [265, 326], presenting additional non-invasive avenues for biomarker discovery in neurological conditions. There has also been some research into circRNA nanoparticle delivery platforms, viral and lipid based, with limited success as the immense complexity of the brain not just in structure but also function has proven quite challenging [327–330]. Additionally, synthetically produced circRNAs aptamers could also be used as a therapeutic themselves to help modulate conditions associated with protein dysfunction such as neurodegenerative conditions [331].

Given that some circRNAs present regulatory patterns enabling their translation into protein sequences [124, 128–132, 332], a comprehensive understanding of the mechanisms underlying their translational capability could facilitate the development of more stable and effective RNA-based therapies. CircRNAs offer advantages over mRNA treatments, including enhanced stability, prolonged translation duration, and reduced immunogenicity. Recently, circRNA-based vaccines have been proposed as innovative strategies for achieving durable and effective expression of viral and cancer antigenic proteins. Examples include circRNAs encoding the SARS-CoV-2 spike protein [333] and charge-altering releasable transporter (CART)-encapsulated circRNAs encoding antigens against targeting cancers [334].

CHALLENGES AND FUTURE DIRECTIONS

Research into circRNAs is still in early stages, particularly regarding their clinical applications in neurological conditions. The high stability of circRNAs compared to mRNA and their cell-specific expression profiles in neurodevelopment and normal brain function make them promising candidates for diagnostics and therapeutics. Using circRNAs as biomarkers for diagnostics may be attainable with machine learning methods and larger sample sizes profiling various biofluids and cellular biopsies, such as serum, saliva, cerebrospinal fluid, and patient-derived cells and tissue cultures. However, the precise mechanisms and impact of circRNA functions in brain homeostasis, as well as their contributions to the etiology of neuropsychiatric and neurodegenerative conditions, require further investigation before their clinical application in therapies can be realized. Moreover, targeting specific brain regions for treatment poses significant challenges, such as overcoming the blood-brain barrier and developing cost-effective, targeted delivery systems for circRNA.

RNA sequencing remains the predominant method for circRNA identification; however, a lack of standardized protocols and detection tools limits precision and specificity [169]. The absence of standardized nomenclature for circRNAs further complicates research communication and replication. Databases such as circBank [153] have incorporated conversion tools to address this issue but incomplete reporting of circRNA transcript lengths, often due to short-read sequencing limitations, persists as a significant challenge. Long-read sequencing technologies, coupled with advanced bioinformatic tools like CIRI-long [176], are beginning to overcome these limitations, enabling precise determination of circRNA structures, interaction sites, and functional roles.

Developing effective and standardized diagnostic biomarkers for neurological conditions has been notoriously difficult. Despite promising studies identifying circRNAs as potential biomarkers, most findings are based on small sample sizes and limited datasets.

The intricate nature of gene expression profiles in the brain and the lack of standardized protocols poses a major hurdle in clinical applications [270, 288, 325, 335]. Larger-scale cohorts and more robust experimental models are required to develop reliable diagnostic panels. Patient-derived neuronal cultures, brain organoids, and animal models offer powerful tools for characterizing circRNA functions and evaluating whether circRNA biogenesis is globally impaired or restricted to specific cell types and brain regions. These models can help elucidate how circRNA dysregulation contributes to clinical features of various neurological disorders.

Importantly, some circRNAs have demonstrated potential for early diagnosis or for predicting disease severity [234, 322, 336]. However, the diversity in patient populations and the cell-specific regulation of circRNA expression require stringent standardization of sample types, biofluids, and cell sources. Combining circRNA biomarkers with other molecular modalities, such as miRNAs and mRNAs could lead to the development of effective diagnostic panels. Ongoing research is uncovering pathways related to circRNA function and biogenesis, highlighting their potential as biomarkers and therapeutic targets. A recent study demonstrated the biological relevance of circRNAs by creating a circRNA-deficient mouse model in which the splice acceptor site for circTulp4 was specifically mutated without affecting the expression of Tulp4 mRNA or protein [83]. This study elegantly demonstrates that circTulp4 plays a critical role in excitatory neurotransmission and sensitivity to aversive stimuli, showing the importance of circRNAs in regulating neuronal functions.

While this study demonstrated that certain regulatory patterns can be modulated to disrupt circRNA expression without affecting the host gene mRNA, canonical splice acceptor-donor sites cannot always be altered without interfering with mRNA splicing. An alternative approach could involve a more detailed investigation into circRNA-specific motif pattern associated with RBPs and co-factors that are directly linked to circRNA backsplicing mechanisms. Understanding these molecular interactions and the precise mechanisms controlling when and how circRNAs are processed could pave the way for novel experimental strategies. These approaches would enable the functional role of circRNAs to be specifically validated, independently of their host gene mRNA, offering deeper insights into their distinct regulatory capabilities.

One significant hurdle to RNA-based therapies, including those involving circRNAs, is the lack of effective delivery systems for synthetic RNAs targeting specific brain cells. Moreover, the stability and toxicity of RNA sequences in human organs and tissues, including the brain, will require substantial advancements in medicinal chemistry before safely moving forward into clinical trials. Promising progress is being made in delivery mechanisms, including nasal spray formulations, ultrasound-based techniques, and vasoactive agents, which may help overcome the blood-brain barrier [191, 337]. Furthermore, the hydrophilic and negatively charged nature of RNA molecules poses several challenges for cellular uptake, emphasizing the need for innovative delivery technologies.

Due to their ability to encode functional peptides, superior stability, and extended lifespan compared to mRNAs, circRNAs offer a promising platform for advancing RNA therapeutics. They hold potential as a powerful tool for pharmaceutical peptide production and gene therapy applications. By overcoming existing challenges related to delivery, stability, and characterization, circRNAs could unlock significant opportunities for individualized therapies of neurological disorders. Translating circRNA research into practical clinical applications could drive the development of innovative diagnostics and therapeutics, addressing critical gaps in the personalized treatment of neurological conditions.

CONCLUSION

Significant advancements have been made in uncovering the functional roles, biogenesis, and molecular mechanisms of

circRNAs in neurological dysfunction. These advancements include neuropsychiatric conditions such as schizophrenia, bipolar disorder, and major depressive disorder, as well as neurodegenerative conditions like Alzheimer's and Parkinson's disease. Insights into the spatio-temporal expression and functional dynamics of circRNAs in these conditions are fostering the development of potential clinical applications. The findings discussed in this review illustrate the intricate regulatory roles circRNAs play in neurological conditions, particularly through interactions with miRNAs and RBPs. Select circRNAs have demonstrated functional effects in model organisms, elucidating their involvement in key neurological pathways. The polygenic nature of these disorders, coupled with their interplay with environmental factors, underscores the need for more advanced model systems. Patient-derived stem cells and differentiated neuronal tissues also offer a promising avenue for identifying novel mechanisms and therapeutic targets, providing valuable insights into human-specific phenotypes. Thus, the role of circRNAs, as non-coding regulatory molecules, represents a transformative shift in our understanding of neurological disorders. Their unique properties and regulatory roles hold promise for the development of more effective diagnostic tools, biomarkers, and therapeutic interventions. This evolving field offers new hope in addressing the complexities of neurological disorders, potentially paving the way for innovative, personalized approaches to treatment and management.

REFERENCES

- Boland CR. Non-coding RNA: it's not junk. *Dig Dis Sci*. 2017;62:1107–09.
- Wu H, Yang L, Chen L-L. The diversity of long noncoding RNAs and their generation. *Trends Genet*. 2017;33:540–52.
- Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, et al. The landscape of long noncoding RNAs in the human transcriptome. *Nat Genet*. 2015;47:199–208.
- Knowling S, Morris KV. Non-coding RNA and antisense RNA. nature's trash or treasure? *Biochimie*. 2011;93:1922–7.
- Mattick JS, Makunin IV. Non-coding RNA. *Hum Mol Genet*. 2006;15:R17–29. Spec No 1
- Fernandes JCR, Acuña SM, Aoki JI, Floeter-Winter LM, Muxel SM. Long non-coding RNAs in the regulation of gene expression: physiology and disease. *Noncoding RNA*. 2019;5:17.
- Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. *Nat Rev Mol Cell Biol*. 2021;22:96–118.
- Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet*. 2019;20:675–91.
- Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with Pre-mRNA splicing. *Mol Cell*. 2014;56:55–66.
- Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential functions. *Development*. 2016;143:1838–47.
- Westholm JO, Miura P, Olson S, Shenker S, Joseph B, Sanfilippo P, et al. Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. *Cell Rep*. 2014;9:1966–80.
- Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA*. 2013;19:141–57.
- Chen L-L, Yang L. Regulation of circRNA biogenesis. *RNA Biol*. 2015;12:381–8.
- Chen L-L. The biogenesis and emerging roles of circular RNAs. *Nat Rev Mol Cell Biol*. 2016;17:205–11.
- Liu X, Hu Z, Zhou J, Tian C, Tian G, He M, et al. Interior circular RNA. *RNA Biol*. 2020;17:87–97.
- Salzman J. Circular RNA expression: its potential regulation and function. *Trends Genet*. 2016;32:309–16.
- Zhao Q, Liu J, Deng H, Ma R, Liao J-Y, Liang H, et al. Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output. *Cell*. 2020;183:76–93.e22.
- Liu X, Wang X, Li J, Hu S, Deng Y, Yin H, et al. Identification of mecciRNAs and their roles in the mitochondrial entry of proteins. *Sci China Life Sci*. 2020;63:1429–49.
- Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. *Proc Natl Acad Sci*. 1976;73:3852–6.
- Tabak HF, Van der Horst G, Smit J, Winter AJ, Mul Y, Koerkamp GMJA. Discrimination between RNA circles, interlocked RNA circles and lariats using two-dimensional polyacrylamide gel electrophoresis. *Nucleic Acids Res*. 1988;16:6597–605.
- Flores R. A naked plant-specific RNA ten-fold smaller than the smallest known viral RNA: the viroid. *C R Acad Sci III*. 2001;324:943–52.
- Becker HF, L'Hermitte-Stead C, Myllykallio H. Diversity of circular RNAs and RNA ligases in archaeal cells. *Biochimie*. 2019;164:37–44.
- Danan M, Schwartz S, Edelheit S, Sorek R. Transcriptome-wide discovery of circular RNAs in Archaea. *Nucleic Acids Res*. 2012;40:3131–42.
- Shen Y, Guo X, Wang W. Identification and characterization of circular RNAs in zebrafish. *FEBS Lett*. 2017;591:213–20.
- Curry-Hyde A, Gray LG, Chen BJ, Ueberham U, Arendt T, Janitz M. Cell type-specific circular RNA expression in human glial cells. *Genomics*. 2020;112:5265–74.
- Dong X, Bai Y, Liao Z, Gritsch D, Liu X, Wang T, et al. Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease. *Nat Commun*. 2023;14:5327.
- Mohamed AS, Abdel-Fattah DS, Abdel-Aleem GA, El-Sheikh TF, Elbatch MM. Biochemical study of the effect of mesenchymal stem cells-derived exosome versus L-Dopa in experimentally induced Parkinson's disease in rats. *Mol Cell Biochem*. 2023;478:2795–811.
- Hanan M, Soreq H, Kadener S. CircRNAs in the brain. *RNA Biol*. 2017;14:1028–34.
- Rybak-Wolf A, Stottmeister C, Glažar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. *Mol Cell*. 2015;58:870–85.
- Baumann K. CircRNAs in lifespan. *Nat Rev Mol Cell Biol*. 2020;21:420–420.
- Cortés-López M, Gruner MR, Cooper DA, Gruner HN, Voda A-I, van der Linden AM, et al. Global accumulation of circRNAs during aging in *Caenorhabditis elegans*. *BMC Genomics*. 2018;19:8.
- Knupp D, Miura P. CircRNA accumulation: a new hallmark of aging? *Mech Ageing Dev*. 2018;173:71–9.
- Basri R, Awan FM, Yang BB, Awan UA, Obaid A, Naz A, et al. Brain-protective mechanisms of autophagy associated circRNAs: Kick starting self-cleaning mode in brain cells via circRNAs as a potential therapeutic approach for neurodegenerative diseases. *Front Mol Neurosci*. 2023;15:1078441.
- Qi J, Meng C, Mo J, Shou T, Ding L, Zhi T. CircAFF2 promotes neuronal cell injury in intracerebral hemorrhage by regulating the miR-488/CLSTN3 axis. *Neuroscience*. 2023;535:75–87.
- Wu Z, Guan Q. hsa_circ_0010889 downregulation inhibits malignant glioma progression by modulating the miR-590-5p/SATB1 axis. *Aging*. 2023;15:7440–50.
- Kang Q, Zhang J, Xie C, Fang S, Chai W. Circular RNA SLC8A1 triggers hippocampal neuronal ferroptosis by regulating FUS-mediated ATF3 mRNA stability in epilepsy. *Exp Cell Res*. 2024;434:113848.
- Wang X, Zhang S, Lv B, Chen H, Zhang W, Dong L, et al. Circular RNA PTP4A2 regulates microglial polarization through STAT3 to promote neuroinflammation in ischemic stroke. *CNS Neurosci Ther*. 2024;30:e14512.
- Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. *Nat Struct Mol Biol*. 2015;22:256–64.
- Xu H, Guo S, Li W, Yu P. The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells. *Sci Rep*. 2015;5:12453.
- Okholm TLH, Sathe S, Park SS, Kamstrup AB, Rasmussen AM, Shankar A, et al. Transcriptome-wide profiles of circular RNA and RNA-binding protein interactions reveal effects on circular RNA biogenesis and cancer pathway expression. *Genome Med*. 2020;12:112.
- Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and microRNAs. *RNA Biol*. 2016;13:34–42.
- Shi X, Liao S, Bi Z, Liu J, Li H, Feng C. Newly discovered circRNAs encoding proteins: recent progress. *Front Genet*. 2023;14:1264606.
- Dong R, Ma X-K, Chen L-L, Yang L. Genome-wide annotation of circRNAs and their alternative back-splicing/splicing with CIRCexplorer pipeline. *Methods Mol Biol*. 2019;1870:137–49.
- Starke S, Jost I, Rossbach O, Schneider T, Schreiner S, Hung L-H, et al. Exon circularization requires canonical splice signals. *Cell Rep*. 2015;10:103–11.
- Zhang X-O, Dong R, Zhang Y, Zhang J-L, Luo Z, Zhang J, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. *Genome Res*. 2016;26:1277–87.
- Zhang X-O, Wang H-B, Zhang Y, Lu X, Chen L-L, Yang L. Complementary sequence-mediated exon circularization. *Cell*. 2014;159:134–47.
- Zhang Y, Zhang X-O, Chen T, Xiang J-F, Yin Q-F, Xing Y-H, et al. Circular intronic long noncoding RNAs. *Mol Cell*. 2013;51:792–806.
- Zheng Y, Ji P, Chen S, Hou L, Zhao F. Reconstruction of full-length circular RNAs enables isoform-level quantification. *Genome Med*. 2019;11:2.

49. Zhong Y, Yang Y, Wang X, Ren B, Wang X, Shan G, et al. Systematic identification and characterization of exon–intron circRNAs. *Genome Res.* 2024;34:376.
50. Awasthi R, Singh AK, Mishra G, Maurya A, Chellappan DK, Gupta G, et al. An overview of circular RNAs. In: Xiao J, editor. *Biological functions of circular RNAs*. Singapore: Springer, 2018. p. 3–14.
51. Conn SJ, Pillman KA, Toubia J, Conn VM, Salmandis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. *Cell.* 2015;160:1125–34.
52. Knupp D, Cooper DA, Saito Y, Darnell RB, Miura P. NOVA2 regulates neural circRNA biogenesis. *Nucleic Acids Res.* 2021;49:6849–62.
53. Ivanov A, Memczak S, Wylter E, Torti F, Porath HT, Orejuela MR, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. *Cell Rep.* 2015;10:170–7.
54. Shen H, An O, Ren X, Song Y, Tang SJ, Ke X-Y, et al. ADARs act as potent regulators of circular transcriptome in cancer. *Nat Commun.* 2022;13:1508.
55. Pisignano G, Michael DC, Visal TH, Pirolog R, Ladomery M, Calin GA. Going circular: history, present, and future of circRNAs in cancer. *Oncogene.* 2023;42:2783–800.
56. Dattilo D, Di Timoteo G, Setti A, Giuliani A, Peruzzi G, Beltran Nebot M, et al. The m6A reader YTHDC1 and the RNA helicase DDX5 control the production of rhabdomyosarcoma-enriched circRNAs. *Nat Commun.* 2023;14:1898.
57. Di Timoteo G, Dattilo D, Centrón-Broco A, Colantoni A, Guarnacci M, Rossi F, et al. Modulation of circRNA Metabolism by m6A Modification. *Cell Rep.* 2020;31:107641.
58. Tang C, Xie Y, Yu T, Liu N, Wang Z, Woolsey RJ, et al. m6A-dependent biogenesis of circular RNAs in male germ cells. *Cell Res.* 2020;30:211–28.
59. Guo JU, Agarwal V, Guo H, Bartel DP. Expanded identification and characterization of mammalian circular RNAs. *Genome Biol.* 2014;15:409.
60. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. *PLoS One.* 2012;7:e30733.
61. Chen L, Wang Y, Lin J, Song Z, Wang Q, Zhao W, et al. Exportin 4 depletion leads to nuclear accumulation of a subset of circular RNAs. *Nat Commun.* 2022;13:5769.
62. Ngo LH, Bert AG, Dredge BK, Williams T, Murphy V, Li W, et al. Nuclear export of circular RNA. *Nature.* 2024;627:212–20.
63. Huang C, Liang D, Tatomer DC, Wilusz JE. A length-dependent evolutionarily conserved pathway controls nuclear export of circular RNAs. *Genes Dev.* 2018;32:639–44.
64. Li Z, Kearse MG, Huang C. The nuclear export of circular RNAs is primarily defined by their length. *RNA Biol.* 2019;16:1–4.
65. Wang S, Latallo MJ, Zhang Z, Huang B, Bobrovnikov DG, Dong D, et al. Nuclear export and translation of circular repeat-containing intronic RNA in C9ORF72-ALS/FTD. *Nat Commun.* 2021;12:4908.
66. Chen R-X, Chen X, Xia L-P, Zhang J-X, Pan Z-Z, Ma X-D, et al. N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMG2A to promote colorectal liver metastasis. *Nat Commun.* 2019;10:4695.
67. Song M, Yao H, Sun Z, Chen D, Xu X, Long G, et al. METTL3/YTHDC1-mediated m6A modification of circRNA3634 regulates the proliferation and differentiation of antler chondrocytes by miR-124486-5-MAPK1 axis. *Cell Mol Biol Lett.* 2023;28:101.
68. Bao C, Lyu D, Huang S. Circular RNA expands its territory. *Mol Cell Oncol.* 2015;3:e1084443.
69. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. *Cell Res.* 2015;25:981–4.
70. Preußner C, Hung L-H, Schneider T, Schreiner S, Hardt M, Moebus A, et al. Selective release of circRNAs in platelet-derived extracellular vesicles. *J Extracell Vesicles.* 2018;7:1424473.
71. Shi X, Wang B, Feng X, Xu Y, Lu K, Sun M. circRNAs and Exosomes: a mysterious frontier for human cancer. *Mol Ther Nucleic Acids.* 2019;19:384.
72. Xu Y, Kong S, Qin S, Shen X, Ju S. Exosomal circRNAs: sorting mechanisms, roles and clinical applications in tumors. *Front Cell Dev Biol.* 2020;8:581558.
73. Zhang F, Jiang J, Qian H, Yan Y, Xu W. Exosomal circRNA: emerging insights into cancer progression and clinical application potential. *J Hematol Oncol.* 2023;16:67.
74. Dou Y, Cha DJ, Franklin JL, Higginbotham JN, Jeppesen DK, Weaver AM, et al. Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes. *Sci Rep.* 2016;6:37982.
75. van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. *Nat Rev Mol Cell Biol.* 2018;19:213–28.
76. Hu Z, Chen G, Zhao Y, Gao H, Li L, Yin Y, et al. Exosome-derived circCCAR1 promotes CD8+ T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. *Mol Cancer.* 2023;22:55.
77. Pan Z, Zhao R, Li B, Qi Y, Qiu W, Guo Q, et al. EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. *Mol Cancer.* 2022;21:16.
78. Shi H, Huang S, Qin M, Xue X, Guo X, Jiang L, et al. Exosomal circ_0088300 derived from cancer-associated fibroblasts acts as a miR-1305 sponge and promotes gastric carcinoma cell tumorigenesis. *Front Cell Dev Biol.* 2021;9:676319.
79. Robinson H, Ruelcke JE, Lewis A, Bond CS, Fox AH, Bharti V, et al. Caveolin-1-driven membrane remodelling regulates hnRNPK-mediated exosomal microRNA sorting in cancer. *Clin Transl Med.* 2021;11:e381.
80. Santangelo L, Giurato G, Cicchini C, Montaldo C, Mancone C, Tarallo R, et al. The RNA-binding protein SYNCRIP is a component of the hepatocyte exosomal machinery controlling microRNA sorting. *Cell Rep.* 2016;17:799–808.
81. Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, Pérez-Hernández D, Vázquez J, Martín-Cofreces N, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. *Nat Commun.* 2013;4:2980.
82. Barbagallo C, Brea D, Caponnetto A, Cirnigliaro M, Scalia M, Magnano A, et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions. *Mol Ther Nucleic Acids.* 2018;12:229.
83. Giusti SA, Pino NS, Pannunzio C, Ogando MB, Armando NG, Garrett L, et al. A brain-enriched circular RNA controls excitatory neurotransmission and restricts sensitivity to aversive stimuli. *Sci Adv.* 2024;10:eadj8769.
84. You X, Vlatkovic I, Babic A, Will T, Epstein I, Tushev G, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. *Nat Neurosci.* 2015;18:603–10.
85. Zhang Y, Xue W, Li X, Zhang J, Chen S, Zhang J-L, et al. The biogenesis of nascent circular RNAs. *Cell Rep.* 2016;15:611–24.
86. Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. *Nucleic Acids Res.* 2016;44:1370–83.
87. Pan Z, Li G-F, Sun M-L, Xie L, Liu D, Zhang Q, et al. MicroRNA-1224 splicing CircularRNA-Filip1I in an Ago2-dependent manner regulates chronic inflammatory pain via targeting Ubr5. *J Neurosci.* 2019;39:2125–43.
88. Hansen TB, Wiklund ED, Bramsen JB, Villadsen SB, Statham AL, Clark SJ, et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. *EMBO J.* 2011;30:4414–22.
89. Piwecka M, Glazar P, Hernandez-Miranda LR, Memczak S, Wolf SA, Rybak-Wolf A, et al. Loss of a mammalian circular RNA locus causes miRNA deregulation and affects brain function. *Science.* 2017;357:eaam8526.
90. Jia R, Xiao M-S, Li Z, Shan G, Huang C. Defining an evolutionarily conserved role of GW182 in circular RNA degradation. *Cell Discov.* 2019;5:1–4.
91. Fischer JW, Busa VF, Shao Y, Leung AKL. Structure-mediated RNA decay by UPF1 and G3BP1. *Mol Cell.* 2020;78:70–84.e6.
92. Li X, Zhang J-L, Lei Y-N, Liu X-Q, Xue W, Zhang Y, et al. Linking circular intronic RNA degradation and function in transcription by RNase H1. *Sci China Life Sci.* 2021;64:1795–809.
93. Burke JM, Gilchrist AR, Sawyer SL, Parker R. RNase L limits host and viral protein synthesis via inhibition of mRNA export. *Sci Adv.* 2021;7:eabh2479.
94. Liu C-X, Li X, Nan F, Jiang S, Gao X, Guo S-K, et al. Structure and degradation of circular RNAs regulate PKR activation in innate immunity. *Cell.* 2019;177:865–80.e21.
95. Zheng Z-M. Circular RNAs and RNase L in PKR activation and virus infection. *Cell Biosci.* 2019;9:43.
96. Guo Y, Guo Y, Chen C, Fan D, Wu X, Zhao L, et al. Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis. *Mol Cancer.* 2021;20:93.
97. Zhang L, Hou C, Chen C, Guo Y, Yuan W, Yin D, et al. The role of N6-methyladenosine (m6A) modification in the regulation of circRNAs. *Mol Cancer.* 2020;19:105.
98. Bartel DP. Metazoan microRNAs. *Cell.* 2018;173:20–51.
99. Shang R, Lee S, Senavirathne G, Lai EC. microRNAs in action: biogenesis, function and regulation. *Nat Rev Genet.* 2023;24:816–33.
100. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. *Nature.* 2013;495:384–8.
101. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature.* 2013;495:333–8.
102. Latreille M, Hausser J, Stützer I, Zhang Q, Hastoy B, Gargani S, et al. MicroRNA-7a regulates pancreatic β cell function. *J Clin Invest.* 2014;124:2722–35.
103. Pollock A, Bian S, Zhang C, Chen Z, Sun T. Growth of the developing cerebral cortex is controlled by microRNA-7 through the p53 pathway. *Cell Rep.* 2014;7:1184–96.

104. Junn E, Lee K-W, Jeong BS, Chan TW, Im J-Y, Mouradian MM. Repression of alpha-synuclein expression and toxicity by microRNA-7. *Proc Natl Acad Sci USA*. 2009;106:13052–7.
105. Zhong Q, Huang J, Wei J, Wu R. Circular RNA CDR1as sponges miR-7-5p to enhance E2F3 stability and promote the growth of nasopharyngeal carcinoma. *Cancer Cell Int*. 2019;19:252.
106. Xu B, Yang T, Wang Z, Zhang Y, Liu S, Shen M. CircRNA CDR1as/miR-7 signals promote tumor growth of osteosarcoma with a potential therapeutic and diagnostic value. *Cancer Manag Res*. 2018;10:4871–80.
107. Hanniford D, Ulloa-Morales A, Karz A, Berzoti-Coelho MG, Moubarak RS, Sánchez-Sendra B, et al. Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis. *Cancer Cell*. 2020;37:55–70.e15.
108. Zhang X, Wang S, Wang H, Cao J, Huang X, Chen Z, et al. Circular RNA circNRP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway. *Mol Cancer*. 2019;18:20.
109. Li Y, Zheng F, Xiao X, Xie F, Tao D, Huang C, et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. *EMBO Rep*. 2017;18:1646–59.
110. Xiao J, Joseph S, Xia M, Teng F, Chen X, Huang R, et al. Circular RNAs acting as miRNAs' sponges and their roles in stem cells. *J Clin Med*. 2022;11:2909.
111. Zhu J, Li Q, Wu Z, Xu W, Jiang R. Circular RNA-mediated miRNA sponge & RNA binding protein in biological modulation of breast cancer. *Non-Coding RNA Res*. 2024;9:262–76.
112. Gallie DR. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. *Genes Dev*. 1991;5:2108–16.
113. Kozak M. How do eucaryotic ribosomes select initiation regions in messenger RNA? *Cell*. 1978;15:1109–23.
114. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. *Cell*. 2009;136:731–45.
115. Gilbert WV. Alternative ways to think about cellular internal ribosome entry. *J Biol Chem*. 2010;285:29033–8.
116. Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, et al. Structure, sequence and expression of the hepatitis delta (delta) viral genome. *Nature*. 1986;323:508–14.
117. Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, et al. Circular transcripts of the testis-determining gene *Sry* in adult mouse testis. *Cell*. 1993;73:1019–30.
118. Chen C, Sarnow P. Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. *Science*. 1995;268:415–7.
119. Abe N, Matsumoto K, Nishihara M, Nakano Y, Shibata A, Maruyama H, et al. Rolling circle translation of circular RNA in living human cells. *Sci Rep*. 2015;5:16435.
120. AbouHaidar MG, Venkataraman S, Golshani A, Liu B, Ahmad T. Novel coding, translation, and gene expression of a replicating covalently closed circular RNA of 220 nt. *Proc Natl Acad Sci USA*. 2014;111:14542–7.
121. Wang Y, Wang Z. Efficient backsplicing produces translatable circular mRNAs. *RNA N Y N*. 2015;21:172–9.
122. Gao X, Xia X, Li F, Zhang M, Zhou H, Wu X, et al. Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling. *Nat Cell Biol*. 2021;23:278–91.
123. Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. *Mol Cell*. 2017;66:22–37.e9.
124. Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Translation of CircRNAs. *Mol Cell*. 2017;66:9–21.e7.
125. Liang W-C, Wong C-W, Liang P-P, Shi M, Cao Y, Rao S-T, et al. Translation of the circular RNA circ β -catenin promotes liver cancer cell growth through activation of the Wnt pathway. *Genome Biol*. 2019;20:84.
126. Mo D, Li X, Raabe CA, Rozhdzhevskiy TS, Skryabin BV, Brosius J. Circular RNA encoded amyloid beta peptides—a novel putative player in Alzheimer's disease. *Cells*. 2020;9:2196.
127. Li Y, Chen B, Zhao J, Li Q, Chen S, Guo T, et al. HNRNPL circularizes ARHGAP35 to produce an oncogenic protein. *Adv Sci*. 2021;8:2001701.
128. Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N⁶-methyladenosine. *Cell Res*. 2017;27:626–41.
129. Chang J, Shin M-K, Park J, Hwang HJ, Locker N, Ahn J, et al. An interaction between eIF4A3 and eIF3g drives the internal initiation of translation. *Nucleic Acids Res*. 2023;51:10950–69.
130. Song Z, Lin J, Su R, Ji Y, Jia R, Li S, et al. eIF3j inhibits translation of a subset of circular RNAs in eukaryotic cells. *Nucleic Acids Res*. 2022;50:11529–49.
131. Wang Y, Wu C, Du Y, Li Z, Li M, Hou P, et al. Expanding uncapped translation and emerging function of circular RNA in carcinomas and noncarcinomas. *Mol Cancer*. 2022;21:13.
132. Weigelt CM, Sehgal R, Tain LS, Cheng J, Eßer J, Pahl A, et al. An insulin-sensitive circular RNA that regulates lifespan in drosophila. *Mol Cell*. 2020;79:268–79.e5.
133. Wu X, Xiao S, Zhang M, Yang L, Zhong J, Li B, et al. A novel protein encoded by circular SMO RNA is essential for Hedgehog signaling activation and glioblastoma tumorigenicity. *Genome Biol*. 2021;22:33.
134. Su R, Zhou M, Lin J, Shan G, Huang C. A circular RNA-gawky-chromatin regulatory axis modulates stress-induced transcription. *Nucleic Acids Res*. 2024;52:3702–21.
135. Yang F, Hu A, Li D, Wang J, Guo Y, Liu Y, et al. Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation. *Mol Cancer*. 2019;18:158.
136. Tay ML-I, Pek JW. Maternally inherited stable intronic sequence RNA triggers a self-reinforcing feedback loop during development. *Curr Biol*. 2017;27:1062–7.
137. Chen N, Zhao G, Yan X, Lv Z, Yin H, Zhang S, et al. A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1. *Genome Biol*. 2018;19:218.
138. Chia F, Liu J, Huang Y-G, Zhang C. A circular RNA derived from DAB1 promotes cell proliferation and osteogenic differentiation of BMSCs via RBP1/DAB1 axis. *Cell Death Dis*. 2020;11:1–11.
139. Li X, Wang J, Zhang C, Lin C, Zhang J, Zhang W, et al. Circular RNA circITGA7 inhibits colorectal cancer growth and metastasis by modulating the Ras pathway and upregulating transcription of its host gene ITGA7. *J Pathol*. 2018;246:166–79.
140. Liu Y, Song J, Liu Y, Zhou Z, Wang X. Transcription activation of circ-STAT3 induced by Gli2 promotes the progression of hepatoblastoma via acting as a sponge for miR-29a/b/c-3p to upregulate STAT3/Gli2. *J Exp Clin Cancer Res*. 2020;39:101.
141. Yu C-Y, Kuo H-C. The emerging roles and functions of circular RNAs and their generation. *J Biomed Sci*. 2019;26:29.
142. Das A, Sinha T, Shyamal S, Panda AC. Emerging role of circular RNA–protein interactions. *Non-Coding RNA*. 2021;7:48.
143. Chen Z, Wang W, Hu S, Sun H, Chen C, Zhang Z, et al. YTHDF2-mediated circYAP1 drives immune escape and cancer progression through activating YAP1/TCF4-PD-L1 axis. *iScience*. 2023;27:108779.
144. Zeng Y, Du WW, Wu Y, Yang Z, Awan FM, Li X, et al. A circular RNA binds to and activates AKT phosphorylation and nuclear localization reducing apoptosis and enhancing cardiac repair. *Theranostics*. 2017;7:3842.
145. Bronisz A, Rooj AK, Krawczyński K, Peruzzi P, Salińska E, Nakano I, et al. The nuclear DICER–circular RNA complex drives the deregulation of the glioblastoma cell microRNAome. *Sci Adv*. 2020;6:eabc0221.
146. Shi L, Liu B, Shen D, Yan P, Zhang Y, Tian Y, et al. A tumor-suppressive circular RNA mediates uncanonical integrin degradation by the proteasome in liver cancer. *Sci Adv*. 2021;7:eabe5043.
147. Du WW, Yang W, Li X, Awan FM, Yang Z, Fang L, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. *Oncogene*. 2018;37:5829–42.
148. Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. *Nucleic Acids Res*. 2016;44:2846–58.
149. Boo SH, Shin M-K, Hwang HJ, Hwang H, Chang S, Kim T, et al. Circular RNAs trigger nonsense-mediated mRNA decay. *Mol Cell*. 2024;84:4862–77.e7.
150. Hafez AK, Zimmerman AJ, Papageorgiou G, Chandrasekaran J, Amoah SK, Lin R, et al. A bidirectional competitive interaction between circHomer1 and Homer1b within the orbitofrontal cortex regulates reversal learning. *Cell Rep*. 2022;38:110282.
151. Chen L, Wang C, Sun H, Wang J, Liang Y, Wang Y, et al. The bioinformatics toolbox for circRNA discovery and analysis. *Brief Bioinform*. 2020. 2020. <https://doi.org/10.1093/bib/bba001>.
152. Glažar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. *RNA*. 2014;20:1666–70.
153. Liu M, Wang Q, Shen J, Yang BB, Ding X. Circbank: a comprehensive database for circRNA with standard nomenclature. *RNA Biol*. 2019;16:899–905.
154. Dong R, Ma X-K, Li G-W, Yang L. CIRCpedia v2: an updated database for comprehensive circular RNA annotation and expression comparison. *Genomics Proteomics Bioinformatics*. 2018;16:226–33.
155. Wu W, Ji P, Zhao F. CircAtlas: an integrated resource of one million highly accurate circular RNAs from 1070 vertebrate transcriptomes. *Genome Biol*. 2020;21:101.
156. Walsh K, Gokool A, Alinejad-Rokny H, Voineagu I. NeuroCirc: an integrative resource of circular RNA expression in the human brain. *Bioinformatics*. 2021;37:3664–6.
157. Ma X-K, Zhai S-N, Yang L. Approaches and challenges in genome-wide circular RNA identification and quantification. *Trends Genet*. 2023;39:897–907.
158. Rebolledo C, Silva JP, Saavedra N, Maracaja-Coutinho V. Computational approaches for circRNAs prediction and in silico characterization. *Brief Bioinform*. 2023;24:bbad154.
159. Nguyen DT, Trac QT, Nguyen T-H, Nguyen H-N, Ohad N, Pawitan Y, et al. Circall: fast and accurate methodology for discovery of circular RNAs from paired-end RNA-sequencing data. *BMC Bioinformatics*. 2021;22:495.

160. Chuang T-J, Wu C-S, Chen C-Y, Hung L-Y, Chiang T-W, Yang M-Y. NCLscan: accurate identification of non-co-linear transcripts (fusion, trans-splicing and circular RNA) with a good balance between sensitivity and precision. *Nucleic Acids Res.* 2016;44:e29.
161. Szabo L, Morey R, Palpant NJ, Wang PL, Afari N, Jiang C, et al. Statistically based splicing detection reveals neural enrichment and tissue-specific induction of circular RNA during human fetal development. *Genome Biol.* 2015;16:126.
162. Ploner A, Calza S, Gusnanto A, Pawitan Y. Multidimensional local false discovery rate for microarray studies. *Bioinformatics.* 2006;22:556–65.
163. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics.* 2013;29:15–21.
164. Gao Y, Zhang J, Zhao F. Circular RNA identification based on multiple seed matching. *Brief Bioinform.* 2018;19:803–10.
165. Cheng J, Metge F, Dieterich C. Specific identification and quantification of circular RNAs from sequencing data. *Bioinformatics.* 2016;32:1094–6.
166. Ma X-K, Wang M-R, Liu C-X, Dong R, Carmichael GG, Chen L-L, et al. CIRCexplorer3: A CLEAR Pipeline for direct comparison of circular and linear RNA Expression. *Genomics Proteomics Bioinformatics.* 2019;17:511–21.
167. Li H, Durbin R. Fast and accurate short read alignment with burrows-wheeler transform. *Bioinforma Oxf Engl.* 2009;25:1754–60.
168. Chen L, Wang F, Bruggeman EC, Li C, Yao B. circMeta: a unified computational framework for genomic feature annotation and differential expression analysis of circular RNAs. *Bioinformatics.* 2020;36:539–45.
169. Vromman M, Anckaert J, Bortoluzzi S, Buratin A, Chen C-Y, Chu Q, et al. Large-scale benchmarking of circRNA detection tools reveals large differences in sensitivity but not in precision. *Nat Methods.* 2023;20:1159–69.
170. Rabin A, Zaffagni M, Ashwal-Fluss R, Patop IL, Jajoo A, Shenzi S, et al. SRCP: a comprehensive pipeline for accurate annotation and quantification of circRNAs. *Genome Biol.* 2021;22:277.
171. Gaffo E, Buratin A, Dal Molin A, Bortoluzzi S. Sensitive, reliable and robust circRNA detection from RNA-seq with CirComPara2. *Brief Bioinform.* 2022;23:bbab418.
172. Digby B, Finn SP, Ó Broin P. nf-core/circrna: a portable workflow for the quantification, miRNA target prediction and differential expression analysis of circular RNAs. *BMC Bioinformatics.* 2023;24:27.
173. Fuchs S, Babin L, Andraos E, Bessiere C, Willier S, Schulte JH, et al. Generation of full-length circular RNA libraries for oxford nanopore long-read sequencing. *PLoS One.* 2022;17:e0273253.
174. Rahimi K, Venø MT, Dupont DM, Kjems J. Nanopore sequencing of brain-derived full-length circRNAs reveals circRNA-specific exon usage, intron retention and microexons. *Nat Commun.* 2021;12:4825.
175. Sonesson C, Yao Y, Bratus-Neuenschwander A, Patrignani A, Robinson MD, Hussain S. A comprehensive examination of nanopore native RNA sequencing for characterization of complex transcriptomes. *Nat Commun.* 2019;10:3359.
176. Hou L, Zhang J, Zhao F. Full-length circular RNA profiling by nanopore sequencing with CIRI-long. *Nat Protoc.* 2023;18:1795–813.
177. Lewis BP, Shih I-H, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian MicroRNA targets. *Cell.* 2003;115:787–98.
178. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. *PLoS Biol.* 2004;2:e363.
179. Krüger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. *Nucleic Acids Res.* 2006;34:W451–W454.
180. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. *Genome Biol.* 2010;11:R90.
181. Armaos A, Colantoni A, Proietti G, Rupert J, Tartaglia GG. catRAPID omics v2.0: going deeper and wider in the prediction of protein–RNA interactions. *Nucleic Acids Res.* 2021;49:W72–W79.
182. Cao C, Yang S, Li M, Li C. CircSSNN: circRNA-binding site prediction via sequence self-attention neural networks with pre-normalization. *BMC Bioinformatics.* 2023;24:220.
183. Dal Molin A, Gaffo E, Difilippo V, Buratin A, Tretti Parenzan C, Bresolin S, et al. CRAFT: a bioinformatics software for custom prediction of circular RNA functions. *Brief Bioinform.* 2022;23:bbab601.
184. Wu H, Liu X, Fang Y, Yang Y, Huang Y, Pan X, et al. Decoding protein binding landscape on circular RNAs with base-resolution transformer models. *Comput Biol Med.* 2024;171:108175.
185. Gong X, Liu Y, Wu G, Xu Z, Zeng L, Tian M, et al. An updated resource for the detection of protein-coding circRNA with CircProPlus. *Sci Rep.* 2024;14:19040.
186. Barbosa DF, Oliveira LS, Nachtigall PG, Valentini Junior R, de Souza N, Paschoal AR, et al. Chapter Nine - cirCodAn: a GHMM-based tool for accurate prediction of coding regions in circRNA. In: Prajapati VK, editor. *Advances in protein chemistry and structural biology.* Vol. 139. Amsterdam, Netherlands: Elsevier; 2024. p. 289–334.
187. Zuo Y, Liu W, Jin Y, Pan Y, Fan T, Fu X, et al. C2CDB: an advanced platform integrating comprehensive information and analysis tools of cancer-related circRNAs. *Bioinforma Adv.* 2024;4:vbae112.
188. Chen X, Han P, Zhou T, Guo X, Song X, Li Y. circRNADb: a comprehensive database for human circular RNAs with protein-coding annotations. *Sci Rep.* 2016;6:34985.
189. Zheng Y, Zhao F. Visualization of circular RNAs and their internal splicing events from transcriptomic data. *Bioinforma Oxf Engl.* 2020;36:2934–5.
190. Feng J, Xiang Y, Xia S, Liu H, Wang J, Ozguc FM, et al. CircView: a visualization and exploration tool for circular RNAs. *Brief Bioinform.* 2019;20:745–51.
191. Sharma D, Sehgal P, Hariprakash J, Sivasubbu S, Scaria V. Methods for annotation and validation of circular RNAs from RNAseq data. *Methods Mol Biol.* 2019;1912:55–76.
192. Tan K-E, Ng WL, Ea C-K, Lim Y-Y. Detection of cytoplasmic and nuclear circular RNA via RT-qPCR. *Bio-Protoc.* 2023;13:e4798.
193. Vromman M, Yigit N, Verniers K, Lefever S, Vandesompele J, Volders P-J. Validation of circular RNAs using RT-qPCR after effective removal of linear RNAs by Ribonuclease R. *Curr Protoc.* 2021;1:e181.
194. Zhong S, Feng J. CircPrimer 2.0: a software for annotating circRNAs and predicting translation potential of circRNAs. *BMC Bioinformatics.* 2022;23:215.
195. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al. Primer3—new capabilities and interfaces. *Nucleic Acids Res.* 2012;40:e115.
196. Singh S, Das A, Panda AC. Sanger sequencing to determine the full-length sequence of circular RNAs. In: Dieterich C, Baudet M-L, editors. *Circular RNA.* New York, NY: Springer US; 2024. p. 93–105.
197. Wang W, Zhu D, Zhao Z, Sun M, Wang F, Li W, et al. RNA sequencing reveals the expression profiles of circRNA and identifies a four-circRNA signature acts as a prognostic marker in esophageal squamous cell carcinoma. *Cancer Cell Int.* 2021;21:151.
198. Xiao M-S, Wilusz JE. An improved method for circular RNA purification using RNase R that efficiently removes linear RNAs containing G-quadruplexes or structured 3' ends. *Nucleic Acids Res.* 2019;47:8755–69.
199. Li S, Li X, Xue W, Zhang L, Yang L-Z, Cao S-M, et al. Screening for functional circular RNAs using the CRISPR–Cas13 system. *Nat Methods.* 2021;18:51–59.
200. Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, et al. Widespread and functional RNA circularization in localized prostate cancer. *Cell.* 2019;176:831–43.e22.
201. Pamudurti NR, Patop IL, Krishnamoorthy A, Ashwal-Fluss R, Bartok O, Kadener S. An in vivo strategy for knockdown of circular RNAs. *Cell Discov.* 2020;6:1–11.
202. Zhang Y, Nguyen TM, Zhang X-O, Wang L, Phan T, Clohessy JG, et al. Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs. *Genome Biol.* 2021;22:41.
203. Gao L, Chang S, Xia W, Wang X, Zhang C, Cheng L, et al. Circular RNAs from BOULE play conserved roles in protection against stress-induced fertility decline. *Sci Adv.* 2020;6:eabb7426.
204. Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. *Nat Commun.* 2016;7:11215.
205. Liang D, Wilusz JE. Short intronic repeat sequences facilitate circular RNA production. *Genes Dev.* 2014;28:2233.
206. Mecozzi N, Nenci A, Vera O, Bok I, Falzone A, DeNicola GM, et al. Genetic tools for the stable overexpression of circular RNAs. *RNA Biol.* 2022;19:353.
207. Petkovic S, Müller S. RNA circularization strategies in vivo and in vitro. *Nucleic Acids Res.* 2015;43:2454.
208. Puttaraju M, Been MD. Group I permuted intron–exon (PIE) sequences self-splice to produce circular exons. *Nucleic Acids Res.* 1992;20:5357–64.
209. Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. *Mol Cell.* 2019;74:508–20.e4.
210. Liu C-X, Chen L-L. Circular RNAs: characterization, cellular roles, and applications. *Cell.* 2022;185:2016–34.
211. Nielsen AF, Bindereif A, Bozzoni I, Hanan M, Hansen TB, Irimia M, et al. Best practice standards for circRNA research. *Nat Methods.* 2022;19:1208–20.
212. Li Q, Lee J-A, Black DL. Neuronal regulation of alternative pre-mRNA splicing. *Nat Rev Neurosci.* 2007;8:819–31.
213. Raj B, Blencowe BJ. Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles. *Neuron.* 2015;87:14–27.
214. Mehta SL, Dempsey RJ, Vemuganti R. Role of circular RNAs in brain development and CNS diseases. *Prog Neurobiol.* 2020;186:101746.
215. Mahmoudi E, Cairns MJ. Circular RNAs are temporospatially regulated throughout development and ageing in the rat. *Sci Rep Nat Publ Group Lond.* 2019;9:2564.
216. Rahimi K, Venø MT, Dupont DM, Kjems J. Nanopore sequencing of brain-derived full-length circRNAs reveals circRNA-specific exon usage, intron retention and microexons. *Nat Commun.* 2021;12:4825.

217. Niu R, Liu J. Circular RNA involvement in aging and longevity. *Curr Genomics*. 2022;23:318–25.
218. Watts ME, Oksanen M, Lejerkran S, Mastropasqua F, Gorospe M, Tammimies K. Circular RNAs arising from synaptic host genes during human neuronal differentiation are modulated by SFPQ RNA-binding protein. *BMC Biol*. 2023;21:127.
219. Kim E, Kim YK, Lee S-JV. Emerging functions of circular RNA in aging. *Trends Genet*. 2021;37:819–29.
220. Li Z, Liu S, Li X, Zhao W, Li J, Xu Y. Circular RNA in schizophrenia and depression. *Front Psychiatry*. 2020;11:392.
221. Song R, Bai Y, Li X, Zhu J, Zhang H, Shi Y, et al. Plasma circular RNA DYM related to major depressive disorder and rapid antidepressant effect treated by visual cortical repetitive transcranial magnetic stimulation. *J Affect Disord*. 2020;274:486–93.
222. Zhou M, Li S, Huang C. Physiological and pathological functions of circular RNAs in the nervous system. *Neural Regen Res*. 2024;19:342.
223. Zimmerman AJ, Hafez AK, Amoah SK, Rodriguez BA, Dell'Orco M, Lozano E, et al. A psychiatric disease-related circular RNA controls synaptic gene expression and cognition. *Mol Psychiatry*. 2020;25:2712–27. <https://doi.org/10.1038/s41380-020-0653-4>
224. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. *Lancet*. 2016;388:86–97.
225. Blokland GAM, Mesholam-Gately RI, Touloupoulou T, del RE EC, Lam M, DeLisi LE, et al. Heritability of neuropsychological measures in schizophrenia and non-psychiatric populations: a systematic review and meta-analysis. *Schizophr Bull*. 2017;43:788–800.
226. van Os J, Kapur S. Schizophrenia. *Lancet*. 2009;374:635–45.
227. Freedman R. Schizophrenia. *N Engl J Med*. 2003;349:1738–49.
228. Castle DJ, Buckley PF. Schizophrenia. Oxford, United Kingdom: Oxford University Press; 2015.
229. Trubetskov V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*. 2022;604:502–8.
230. Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511:421–7.
231. Singh M, Dwibedy SLL, Biswal SR, Muthuswamy S, Kumar A, Kumar S. Circular RNA: a novel and potential regulator in pathophysiology of schizophrenia. *Metab Brain Dis*. 2022;37:1309–16.
232. Huang H, Luo J, Qi Y, Wu Y, Qi J, Yan X, et al. Comprehensive analysis of circRNA expression profile and circRNA-miRNA-mRNA network susceptibility to very early-onset schizophrenia. *Schizophrenia*. 2023;9:1–10.
233. Liao F, Zhu L, Yang J, Wu X, Zhao Z, Xu B, et al. Whole transcriptome sequencing identified CircRNA profiles and the related networks in schizophrenia. *J Mol Neurosci*. 2022;72:1622–35.
234. Mahmoudi E, Green MJ, Cairns MJ. Dysregulation of circRNA expression in the peripheral blood of individuals with schizophrenia and bipolar disorder. *J Mol Med*. 2021;99:981–91.
235. Yang J, Long Q, Zhang Y, Liu Y, Wu J, Zhao X, et al. Whole transcriptome analysis reveals dysregulation of molecular networks in schizophrenia. *Asian J Psychiatry*. 2023;85:103649.
236. Mahmoudi E, Fitzsimmons C, Geaghan MP, Shannon Weickert C, Atkins JR, Wang X, et al. Circular RNA biogenesis is decreased in postmortem cortical gray matter in schizophrenia and may alter the bioavailability of associated miRNA. *Neuropsychopharmacology*. 2019;44:1043–54.
237. Mai T-L, Chen C-Y, Chen Y-C, Chiang T-W, Chuang T-J. Trans-genetic effects of circular RNA expression quantitative trait loci and potential causal mechanisms in autism. *Mol Psychiatry*. 2022;27:4695–706.
238. Åberg K, Saetre P, Lindholm E, Ekholm B, Pettersson U, Adolfsen R, et al. Human QKI, a new candidate gene for schizophrenia involved in myelination. *Am J Med Genet B Neuropsychiatr Genet*. 2006;141B:84–90.
239. Silberger G, Lundin D, Navon R, Öhman M. Deregulation of the A-to-I RNA editing mechanism in psychiatric disorders. *Hum Mol Genet*. 2012;21:311–21.
240. Liu Z, Ran Y, Tao C, Li S, Chen J, Yang E. Detection of circular RNA expression and related quantitative trait loci in the human dorsolateral prefrontal cortex. *Genome Biol*. 2019;20:99.
241. Südhof TC. Synaptic neuexin complexes: a molecular code for the logic of neural circuits. *Cell*. 2017;171:745–69.
242. Dai J, Aoto J, Südhof TC. Alternative splicing of presynaptic neuexins differentially controls postsynaptic NMDA and AMPA receptor responses. *Neuron*. 2019;102:993–1008.e5.
243. Kirov G, Rujescu D, Ingason A, Collier DA, O'Donovan MC, Owen MJ. Neuexin 1 (NRXN1) deletions in schizophrenia. *Schizophr Bull*. 2009;35:851–4.
244. Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. *PLoS Genet*. 2009;5:e1000373.
245. Rujescu D, Ingason A, Cichon S, Pietiläinen OPH, Barnes MR, Touloupoulou T, et al. Disruption of the neuexin 1 gene is associated with schizophrenia. *Hum Mol Genet*. 2009;18:988–96.
246. Weissleder C, Webster MJ, Barry G, Shannon Weickert C. Reduced insulin-like growth factor family member expression predicts neurogenesis marker expression in the subependymal zone in schizophrenia and bipolar disorder. *Schizophr Bull*. 2021;47:1168–78.
247. Hu J-H, Park JM, Park S, Xiao B, Dehoff MH, Kim S, et al. Homeostatic scaling requires group I mGluR activation mediated by Homer1a. *Neuron*. 2010;68:1128–42.
248. Ehlers MD. Synapse structure: glutamate receptors connected by the shanks. *Curr Biol*. 1999;9:R848–50.
249. Craddock N, Sklar P. Genetics of bipolar disorder. *Lancet Lond Engl*. 2013;381:1654–62.
250. O'Connell KS, Coombes BJ. Genetic contributions to bipolar disorder: current status and future directions. *Psychol Med*. 2021;51:2156–67.
251. Prata DP, Costa-Neves B, Cosme G, Vassos E. Unravelling the genetic basis of schizophrenia and bipolar disorder with GWAS: a systematic review. *J Psychiatr Res*. 2019;114:178–207.
252. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat Genet*. 2021;53:817–29.
253. Fu Y, He W, Zhou C, Fu X, Wan Q, He L, et al. Bioinformatics analysis of circRNA expression and construction of "circRNA-miRNA-mRNA" competing endogenous RNAs networks in bipolar disorder patients. *Front Genet*. 2021;12:718976.
254. Lin R, Lopez JP, Cruceanu C, Pierotti C, Fiori LM, Squassina A, et al. Circular RNA circCCNT2 is upregulated in the anterior cingulate cortex of individuals with bipolar disorder. *Transl Psychiatry*. 2021;11:1–8.
255. Luykx JJ, Giuliani F, Giuliani G, Veldink J. Coding and non-coding RNA abnormalities in bipolar disorder. *Genes*. 2019;10:946.
256. Lu B, Su Y, Das S, Liu J, Xia J, Ren D. The neuronal channel NALCN contributes resting sodium permeability and is required for normal respiratory rhythm. *Cell*. 2007;129:91–83.
257. De Luca A, De Falco M, Baldi A, Paggi MG. Cyclin T: Three forms for different roles in physiological and pathological functions. *J Cell Physiol*. 2003;194:101–7.
258. Lohoff FW. Overview of the genetics of major depressive disorder. *Curr Psychiatry Rep*. 2010;12:539–46.
259. Filatova EV, Shadrina MI, Slominsky PA. Major depression: one brain, one disease, one set of intertwined processes. *Cells*. 2021;10:1283.
260. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet*. 2018;50:668–81.
261. Flint J. The genetic basis of major depressive disorder. *Mol Psychiatry*. 2023;28:2254–65.
262. Zhao Y, Zhang Q, Yan Y, Wang X, Shao Y, Mei C, et al. Antidepressant-like effects of geniposide in chronic unpredictable mild stress-induced mice by regulating the circ_0008405/miR-25-3p/Gata2 and Oip50s1/miR-25-3p/Gata2 networks. *Phytother Res*. 2023;37:1850–63.
263. Gan H, Lei Y, Yuan N, Tang K, Hao W, Ma Q, et al. Circular RNAs in depression: Biogenesis, function, expression, and therapeutic potential. *Biomed Pharmacother*. 2021;137:11244.
264. Zhou S, Chen R, She Y, Liu X, Zhao H, Li C, et al. A new perspective on depression and neuroinflammation: non-coding RNA. *J Psychiatr Res*. 2022;148:293–306.
265. Shi Y, Song R, Wang Z, Zhang H, Zhu J, Yue Y, et al. Potential clinical value of circular RNAs as peripheral biomarkers for the diagnosis and treatment of major depressive disorder. *EBioMedicine*. 2021;66:103337.
266. Zhang Y, Du L, Bai Y, Han B, He C, Gong L, et al. CircDYM ameliorates depressive-like behavior by targeting miR-9 to regulate microglial activation via HSP90 ubiquitination. *Mol Psychiatry*. 2020;25:1175–90.
267. Ma Z-Y, Chen F, Xiao P, Zhang X-M, Gao X-X. Silence of MiR-9 protects depression mice through Notch signaling pathway. *Eur Rev Med Pharmacol Sci*. 2019;23:4961–70.
268. He C, Wang Q, Xie C. miR-9 could mediate the relationship between childhood maltreatment and depression. *Alzheimers Dement*. 2020;16:e043590.
269. Xian X, Cai L-L, Li Y, Wang R-C, Xu Y-H, Chen Y-J, et al. Neuron secrete exosomes containing miR-9-5p to promote polarization of M1 microglia in depression. *J Nanobiotechnology*. 2022;20:122.
270. Meng P, Zhang X, Liu T-T, Liu J, Luo Y, Xie M-X, et al. A whole transcriptome profiling analysis for antidepressant mechanism of Xiaoyaosan mediated synapse loss via BDNF/trkB/PI3K signal axis in CUMS rats. *BMC Complement Med Ther*. 2023;23:198.
271. Choi M, Wang SE, Ko SY, Kang HJ, Chae SY, Lee SH, et al. Overexpression of human GATA-1 and GATA-2 interferes with spine formation and produces depressive behavior in rats. *PLoS One*. 2014;9:e109253.
272. Lane CA, Hardy J, Schott JM. Alzheimer's disease. *Eur J Neurol*. 2018;25:59–70.
273. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. *Cell*. 2012;148:1204–22.

274. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nat Genet.* 2021;53:1276–82.
275. Andrews SJ, Renton AE, Fulton-Howard B, Podlesny-Drabiniok A, Marcora E, Goate AM. The complex genetic architecture of Alzheimer's disease: novel insights and future directions. *eBioMedicine.* 2023;90:104511.
276. Wang E, Lemos Duarte M, Rothman LE, Cai D, Zhang B. Non-coding RNAs in Alzheimer's disease: perspectives from omics studies. *Hum Mol Genet.* 2022;31:R54–R61.
277. Rybak-Wolf A, Plass M. RNA dynamics in Alzheimer's disease. *Molecules.* 2021;26:5113.
278. Dube U, Del-Aguila JL, Li Z, Budde JP, Jiang S, Hsu S, et al. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. *Nat Neurosci.* 2019;22:1903–12.
279. Song C, Zhang Y, Huang W, Shi J, Huang Q, Jiang M, et al. Circular RNA Cwc27 contributes to Alzheimer's disease pathogenesis by repressing Pur- α activity. *Cell Death Differ.* 2022;29:393–406.
280. Puri S, Hu J, Sun Z, Lin M, Stein TD, Farrer LA, et al. Identification of circRNAs linked to Alzheimer's disease and related dementias. *Alzheimers Dement.* 2023;19:3389–405.
281. Wang X, Xie J, Tan L, Lu Y, Shen N, Li J, et al. N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease. *Transl Neurodegener.* 2023;12:53.
282. Liu L, Chen X, Chen Y-H, Zhang K. Identification of circular RNA hsa_circ_0003391 in peripheral blood is potentially associated with Alzheimer's disease. *Front Aging Neurosci.* 2020;12:601965.
283. Cochran KR, Veeraraghavan K, Kundu G, Mazan-Mamczarz K, Coletta C, Thambisetty M, et al. Systematic identification of circRNAs in Alzheimer's disease. *Genes.* 2021;12:1258.
284. Zheng D, Tahir RA, Yan Y, Zhao J, Quan Z, Kang G, et al. Screening of human circular RNAs as biomarkers for early onset detection of Alzheimer's disease. *Front Neurosci.* 2022;16:878287.
285. Ren Z, Chu C, Pang Y, Cai H, Jia L. A circular RNA blood panel that differentiates Alzheimer's disease from other dementia types. *Biomark Res.* 2022;10:63.
286. Piscopo P, Manzini V, Rivabene R, Crestini A, Le Pera L, Pizzi E, et al. A plasma circular RNA profile differentiates subjects with Alzheimer's disease and mild cognitive impairment from healthy controls. *Int J Mol Sci.* 2022;23:13232.
287. Smukowski SN, Danyko C, Somberg J, Kaufman EJ, Course MM, Postupna N, et al. mRNA and circRNA mislocalization to synapses are key features of Alzheimer's disease. *PLOS Genet.* 2024;20:e1011359.
288. Lo IJ, Hill J, Vilhjalmsdottir BJ, Kjems J. Linking the association between circRNAs and Alzheimer's disease progression by multi-tissue circular RNA characterization. *RNA Biol.* 2020;17:1789–97.
289. Gao Y, Xu S-M, Cheng Y, Takenaka K, Lindner G, Janitz M. Investigation of the circular transcriptome in Alzheimer's disease brain. *J Mol Neurosci.* 2024;74:64.
290. Sanadgol N, Amini J, Beyer C, Zendedel A. Presenilin-1-derived circular RNAs: neglected epigenetic regulators with various functions in Alzheimer's disease. *Biomolecules.* 2023;13:1401.
291. Klüppel M, Wrana JL. Turning it up a Notch: cross-talk between TGF β and Notch signaling. *BioEssays.* 2005;27:115–8.
292. Kapoor A, Nation DA. Role of Notch signaling in neurovascular aging and Alzheimer's disease. *Semin Cell Dev Biol.* 2021;116:90–97.
293. Kapoor M, Chinnathambi S. TGF- β 1 signalling in Alzheimer's pathology and cytoskeletal reorganization: a specialized Tau perspective. *J Neuroinflammation.* 2023;20:72.
294. Chen H-H, Eteleeb A, Wang C, Fernandez MV, Budde JP, Bergmann K, et al. Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease. *Acta Neuropathol Commun.* 2022;10:29.
295. Brigman JL, Daut RA, Wright T, Gunduz-Cinar O, Graybeal C, Davis MI, et al. GluN2B in corticostriatal circuits governs choice learning and choice shifting. *Nat Neurosci.* 2013;16:1101–10.
296. Schmidt MF, Gan ZY, Komander D, Dewson G. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities. *Cell Death Differ.* 2021;28:570–90.
297. Blalock EM, Buechel HM, Popovic J, Geddes JW, Landfield PW. Microarray analyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incipient Alzheimer's disease. *J Chem Neuroanat.* 2011;42:118–26.
298. Miller JA, Woltjer RL, Goodenbour JM, Horvath S, Geschwind DH. Genes and pathways underlying regional and cell type changes in Alzheimer's disease. *Genome Med.* 2013;5:48.
299. Wang M, Roussos P, McKenzie A, Zhou X, Kajiwara Y, Brennand KJ, et al. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. *Genome Med.* 2016;8:104.
300. Hosseini S, Arefian E, Rakhsh-Khorshid H, Eivani M, Rezayof A, Pezeshk H, et al. A meta-analysis of gene expression data highlights synaptic dysfunction in the hippocampus of brains with Alzheimer's disease. *Sci Rep.* 2020;10:8384.
301. Rodriguez-Muñoz A, Liquori A, García-Bohorquez B, Jajto T, Aller E, Millán JM, et al. Functional assays of non-canonical splice-site variants in inherited retinal dystrophies genes. *Sci Rep.* 2022;12:68.
302. Bloem BR, Okun MS, Klein C. Parkinson's disease. *Lancet.* 2021;397:2284–303.
303. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkman J, et al. Parkinson disease. *Nat Rev Dis Primer.* 2017;3:1–21.
304. Kim JJ, Vitale D, Otani DV, Lian MM, Heilbron K, Iwaki H, et al. Multi-ancestry genome-wide association meta-analysis of Parkinson's disease. *Nat Genet.* 2024;56:27–36.
305. Whittle BJ, Izuogu OG, Lowes H, Deen D, Pyle A, Coxhead J, et al. Early-stage idiopathic Parkinson's disease is associated with reduced circular RNA expression. *NPJ Park Dis.* 2024;10:25.
306. Huang Z, Song E, Chen Z, Yu P, Chen W, Lin H. Integrated bioinformatics analysis for exploring potential biomarkers related to Parkinson's disease progression. *BMC Med Genomics.* 2024;17:133.
307. Beric A, Sun Y, Sanchez S, Martin C, Powell T, Kumar R, et al. Circulating blood circular RNA in Parkinson's disease; from involvement in pathology to diagnostic tools in at-risk individuals. *Npj Park Dis.* 2024;10:1–14.
308. Wang Q, Wang H, Zhao X, Han C, Liu C, Li Z, et al. Transcriptome sequencing of circular RNA reveals the involvement of hsa_circMHI_0001 in the pathogenesis of Parkinson's disease. *CNS Neurosci Ther.* 2024;30:e14435.
309. Kong F, Lv Z, Wang L, Zhang K, Cai Y, Ding Q, et al. RNA-sequencing of peripheral blood circular RNAs in Parkinson disease. *Medicine.* 2021;100:e25888.
310. Ravanidis S, Bougea A, Karampatsi D, Papagiannakis N, Maniati M, Stefanis L, et al. Differentially expressed circular RNAs in peripheral blood mononuclear cells of patients with Parkinson's disease. *Mov Disord.* 2021;36:1170–9.
311. Sang Q, Liu X, Wang L, Qi L, Sun W, Wang W, et al. CircSNCA downregulation by pramipexole treatment mediates cell apoptosis and autophagy in Parkinson's disease by targeting miR-7. *Aging.* 2018;10:1281–93.
312. Zhou Z, Niu Y, Huang G, Lu J, Chen A, Zhu L. Silencing of circRNA.2837 plays a protective role in sciatic nerve injury by sponging the miR-34 family via regulating neuronal autophagy. *Mol Ther Nucleic Acids.* 2018;12:718–29.
313. Hanan M, Simchovitz A, Yayon N, Vaknine S, Cohen-Fultheim R, Karmon M, et al. A Parkinson's disease CircRNAs resource reveals a link between circSLC8A1 and oxidative stress. *EMBO Mol Med.* 2020;12:e11942.
314. Feng Z, Zhang L, Wang S, Hong Q. Circular RNA circDLGAP4 exerts neuroprotective effects via modulating miR-134-5p/CREB pathway in Parkinson's disease. *Biochem Biophys Res Commun.* 2020;522:388–94.
315. Wang W, Lv R, Zhang J, Liu Y. circSAMD4A participates in the apoptosis and autophagy of dopaminergic neurons via the miR-29c-3p-mediated AMPK/mTOR pathway in Parkinson's disease. *Mol Med Rep.* 2021;24:540.
316. Liu Q, Li Q, Zhang R, Wang H, Li Y, Liu Z, et al. circ-Pank1 promotes dopaminergic neuron neurodegeneration through modulating miR-7a-5p/ α -syn pathway in Parkinson's disease. *Cell Death Dis.* 2022;13:1–11.
317. Zhou Y, Liu Y, Kang Z, Yao H, Song N, Wang M, et al. CircEPS15, as a sponge of MIR24-3p ameliorates neuronal damage in Parkinson disease through boosting PINK1-PRKN-mediated mitophagy. *Autophagy.* 2023;19:2520–37.
318. Mehta SL, Chokkalla AK, Bathula S, Arruri V, Chelluboina B, Vemuganti R. CDR1as regulates α -synuclein-mediated ischemic brain damage by controlling miR-7 availability. *Mol Ther Nucleic Acids.* 2023;31:57–67.
319. Zhang Y-J, Zhu W-K, Qi F-Y, Che F-Y. CircHIPK3 promotes neuroinflammation through regulation of the miR-124-3p/STAT3/NLRP3 signaling pathway in Parkinson's disease. *Adv Clin Exp Med.* 2023;32:315–29.
320. Zhong C, Zhang Q, Bao H, Li Y, Nie C. Hsa_circ_0054220 upregulates HMGA1 by the competitive RNA pattern to promote neural impairment in MPTP model of Parkinson's disease. *Appl Biochem Biotechnol.* 2023. <https://doi.org/10.1007/s12010-023-04740-2>.
321. Lin X, Mao L, Chen Q, Wang T, Tao T, Pan L. CircHIVEP2 alleviates Parkinson's nerve damage and inflammatory response by targeting miR-485-3p. *Exp Gerontol.* 2024;188:112387.
322. Zhong L, Ju K, Chen A, Cao H. Circulating circRNAs panel acts as a biomarker for the early diagnosis and severity of Parkinson's disease. *Front Aging Neurosci.* 2021;13:684289.
323. Tan G, Wang L, Liu Y, Zhang H, Feng W, Liu Z. The alterations of circular RNA expression in plasma exosomes from patients with schizophrenia. *J Cell Physiol.* 2021;236:458–67.
324. He J, Ren M, Li H, Yang L, Wang X, Yang Q. Exosomal circular RNA as a biomarker platform for the early diagnosis of immune-mediated demyelinating disease. *Front Genet.* 2019;10:860.

325. Yu Z, Li Y. Association of autonomic symptoms with cerebrospinal fluid biomarkers in Parkinson disease and scans without evidence of dopaminergic deficit. *Medicine*. 2021;100:e24837.
326. Bahn JH, Zhang Q, Li F, Chan T-M, Lin X, Kim Y, et al. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. *Clin Chem*. 2015;61:221–30.
327. Borrajo ML, Alonso MJ. Using nanotechnology to deliver biomolecules from nose to brain — peptides, proteins, monoclonal antibodies and RNA. *Drug Deliv Transl Res*. 2022;12:862–80.
328. Grabrucker AM, Ruozi B, Belletti D, Pederzoli F, Forni F, Vandelli MA, et al. Nanoparticle transport across the blood brain barrier. *Tissue Barriers*. 2016;4:e1153568.
329. Sharma RK, Calderon C, Vivas-Mejia PE. Targeting non-coding RNA for Glioblastoma therapy: the challenge of overcomes the blood-brain barrier. *Front Med Technol*. 2021;3:678593.
330. Xiong R, Ling G, Zhang Y, Guan J, Zhang P. Nucleic acid delivery by ionizable nanocarriers for brain disease treatment. *Brain-X*. 2023;1:e7.
331. Litke JL, Jaffrey SR. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. *Nat Biotechnol*. 2019;37:667–75.
332. Chen C-K, Cheng R, Demeter J, Chen J, Weingarten-Gabbay S, Jiang L, et al. Structured elements drive extensive circular RNA translation. *Mol Cell*. 2021;81:4300–18.e13.
333. Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. *Cell*. 2022;185:1728–44.e16.
334. Amaya L, Grigoryan L, Li Z, Lee A, Wender PA, Pulendran B, et al. Circular RNA vaccine induces potent T cell responses. *Proc Natl Acad Sci*. 2023;120:e2302191120.
335. Zhang Z, Yang T, Xiao J. Circular RNAs: promising biomarkers for human diseases. *EBioMedicine*. 2018;34:267–74.
336. Yao G, Niu W, Zhu X, He M, Kong L, Chen S, et al. hsa_circRNA_104597: a novel potential diagnostic and therapeutic biomarker for schizophrenia. *Biomark Med*. 2019;13:331–40.
337. Li M-X, Weng J-W, Ho ES, Chow SF, Tsang CK. Brain delivering RNA-based therapeutic strategies by targeting mTOR pathway for axon regeneration after central nervous system injury. *Neural Regen Res*. 2022;17:2157–65.

ACKNOWLEDGEMENTS

OH received support from Griffith University Postgraduate Research Scholarship. ASC thanks Griffith University, philanthropic donations and NHMRC Medical Research Future Funds (App# 2017861) for financial support.

AUTHOR CONTRIBUTIONS

ASC coordinated the study. ASC, OH and AMS collaboratively designed the study, conducted the literature review, and critically interpreted the data. ASC, OH and AMS participated in discussions, contributed to manuscript drafting and revisions, and approved the final version for submission.

FUNDING

Open Access funding enabled and organized by CAUL and its Member Institutions.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Alexandre S. Cristiano.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© Crown 2025